U.S. patent application number 11/490686 was filed with the patent office on 2007-01-18 for alpha-msh related compounds and methods of use.
This patent application is currently assigned to MGI PHARMA Biologics, Inc., a Delaware corporation. Invention is credited to Nazneen Aziz, Hongmin Chen, Bijan Etemad-Moghadam, Mary Lynne Hedley, Robert G. Urban, Peng Yin.
Application Number | 20070015257 11/490686 |
Document ID | / |
Family ID | 27539765 |
Filed Date | 2007-01-18 |
United States Patent
Application |
20070015257 |
Kind Code |
A1 |
Hedley; Mary Lynne ; et
al. |
January 18, 2007 |
Alpha-MSH related compounds and methods of use
Abstract
The invention provides polypeptides containing .alpha.-MSH that
can be used to treat diseases characterized by inflammation and/or
autoimmunity. Also included in the invention are .alpha.-MSH
analogs and nucleic acids encoding polypeptides containing
.alpha.-MSH and .alpha.-MSH analogs optionally linked to
heterologous sequences. Also included in the invention are methods
of delivering .alpha.-MSH containing peptides, .alpha.-MSH analogs,
an DNA encoding .alpha.-MSH and .alpha.-MSH analogs.
Inventors: |
Hedley; Mary Lynne;
(Lexington, MA) ; Urban; Robert G.; (Lexington,
MA) ; Aziz; Nazneen; (Lexington, MA) ; Chen;
Hongmin; (Framingham, MA) ; Etemad-Moghadam;
Bijan; (Jamaica Plain, MA) ; Yin; Peng;
(Newton, MA) |
Correspondence
Address: |
FISH & RICHARDSON PC
P.O. BOX 1022
MINNEAPOLIS
MN
55440-1022
US
|
Assignee: |
MGI PHARMA Biologics, Inc., a
Delaware corporation
|
Family ID: |
27539765 |
Appl. No.: |
11/490686 |
Filed: |
July 21, 2006 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
09906206 |
Jul 16, 2001 |
|
|
|
11490686 |
Jul 21, 2006 |
|
|
|
60218381 |
Jul 14, 2000 |
|
|
|
60226382 |
Aug 18, 2000 |
|
|
|
60238380 |
Oct 6, 2000 |
|
|
|
60258764 |
Dec 29, 2000 |
|
|
|
60298317 |
Jun 14, 2001 |
|
|
|
Current U.S.
Class: |
435/69.4 ;
435/320.1; 435/325; 514/10.7; 514/10.8; 514/12.2; 530/399;
536/23.5 |
Current CPC
Class: |
A61P 19/02 20180101;
C07K 2319/00 20130101; C07K 2319/02 20130101; A61P 25/00 20180101;
A61P 3/04 20180101; C07K 14/685 20130101; A61P 27/02 20180101; A61P
29/00 20180101; A61P 31/04 20180101; A61P 3/06 20180101; A61K 38/00
20130101; A61P 37/00 20180101; A61P 3/10 20180101; A61P 37/06
20180101; A61P 17/00 20180101; A61P 11/06 20180101; A61P 1/04
20180101; C07K 2319/50 20130101; A61P 17/06 20180101; A61P 1/16
20180101 |
Class at
Publication: |
435/069.4 ;
435/320.1; 435/325; 530/399; 536/023.5; 514/012 |
International
Class: |
A61K 38/22 20060101
A61K038/22; C07H 21/04 20060101 C07H021/04; A61K 38/34 20060101
A61K038/34; C07K 14/68 20060101 C07K014/68 |
Claims
1. A nucleic acid comprising a sequence encoding a fusion
polypeptide comprising an .alpha.-MSH concatamer, .alpha.-MSH and a
membrane sequence, .alpha.-MSH and a signal sequence, or
.alpha.-MSH and a glycosylphosphatidylinositol (GPI) attachment
signal peptide.
2-18. (canceled)
19. An expression vector comprising the nucleic acid of claim
1.
20. A method of making a polypeptide, the method comprising
maintaining a cell containing an expression vector comprising the
nucleic acid of claim 1 under conditions permitting expression of
the polypeptide of claim 1.
21. A method of treatment comprising delivering the nucleic acid of
claim 1 to an individual suffering from, or at risk of, a disorder
of the immune system.
22. The method of claim 21, wherein the individual has an
inflammatory disorder.
23. The method of claim 21, wherein the individual has an
autoimmune disorder.
24. A composition comprising a fusion polypeptide comprising an
.alpha.-MSH concatamer, .alpha.-MSH and a membrane sequence,
.alpha.-MSH and a signal sequence, or .alpha.-MSH and a GPI
attachment signal peptide.
25. The composition of claim 24, the composition further comprising
a therapeutic compound.
26-28. (canceled)
29. A composition comprising a delivery vehicle and the nucleic
acid of claim 1.
30. The composition of claim 29, wherein the delivery vehicle is
selected from the group consisting of a microsphere, a liposome, a
suspension, a particulate and an Immune Stimulating Complex
(ISCOM).
31. A method of generating regulatory T cells, the method
comprising: providing a population of T cells in vitro; and mixing
the population of T cells with an .alpha.-MSH analog and a
therapeutic compound; wherein the mixing results in the generation
of regulatory T cells in vitro.
32. A method of generating regulatory T cells, the method
comprising administering to an individual an .alpha.-MSH analog and
a therapeutic compound, wherein the administration results in the
generation of regulatory T cells in the individual.
33. A nucleic acid comprising a sequence encoding a fusion
polypeptide comprising an .alpha.-MSH analog concatamer, an
.alpha.-MSH analog and a membrane sequence, an .alpha.-MSH analog
and a signal sequence, or an .alpha.-MSH analog and a GPI
attachment signal peptide.
34-36. (canceled)
37. A method of treatment comprising delivering a therapeutic
compound and an .alpha.-MSH-containing polypeptide to an individual
suffering from, or at risk of, a disorder of the immune system.
38. A method of treatment comprising delivering a therapeutic
compound and a nucleic acid encoding an .alpha.-MSH-containing
polypeptide to an individual suffering from, or at risk of, a
disorder of the immune system.
Description
CROSS REFERENCE TO RELATED APPLICATIONS
[0001] This application claims priority from U.S. Provisional
Application No. 60/218,381, filed Jul. 14, 2000, U.S. Provisional
Application No. 60/226,382, filed Aug. 18, 2000, U.S. Provisional
Application No. 60/238,380, filed Oct. 6, 2000, U.S. Provisional
Application No. 60/258,764, filed Dec. 29, 2000, and U.S.
Provisional Application No. 60/298,317, filed Jun. 14, 2001. These
applications are incorporated herein by reference in their
entirety.
FIELD OF THE INVENTION
[0002] The invention relates to alpha-MSH compounds and methods of
use.
BACKGROUND
[0003] Pro-opiomelanocortin (POMC) is a precursor of various
bioactive peptides, including adrenocorticotropic hormone (ACTH)
and alpha MSH (.alpha.-MSH). .alpha.-MSH and ACTH are members of
the melanocortin family, which also includes .beta.-MSH and
.gamma.-MSH. POMC contains eight pairs of basic amino acids and one
sequence of four basic amino acids, which are the sites of cleavage
for the enzymes prohormone convertase 1 (PC1) and prohormone
convertase 2 (PC2). Specifically, PC1 cleaves the POMC polypeptide
to yield ACTH(1-39), which is in turn cleaved by PC2 to yield
ACTH(1-17), which is further cleaved by PC2 to result in
ACTH(1-14). A 13 amino acid .alpha.-MSH peptide is generated by the
action of peptidylglycine alpha-amidating monooxygenase, which
results in a C-terminally amidated .alpha.-MSH peptide. ACTH(1-17)
contains the consensus amidation signal of Gly-Lys-Lys immediately
carboxy the valine residue at position 13. This valine residue is
subject to amidation in .alpha.-MSH and ACTH peptides. Further
enzymatic modifications including N-alpha-acetylation by
opiomelanotropin-acetyltransferase can occur during or after
proteolytic processing. .alpha.-MSH and ACTH can be produced in
amidated or non-amidated forms, as well as des-acetylated,
mono-acetylated or di-acetylated forms. C-terminal amidation and/or
N-terminal acetylation may contribute to the biological activity of
.alpha.-MSH and/or ACTH peptides.
[0004] Under normal conditions the level of .alpha.-MSH is tightly
regulated, having a half-life in the circulation on the order of a
few minutes (Lipton et al. (1990) Yale J. Biol. Med. 63:173).
.alpha.-MSH is found in the circulation of normal individuals at a
level of about 21 pg/ml. .alpha.-MSH is also found in the aqueous
humor of the eye (Taylor et al. (1992) Curr. Eye Res. 11:1199),
cerebral spinal fluid (Taylor et al. (1996) Neuroimmunomod. 3:112),
in skin (Luger et al. (1997) J. Invest. Dermatol. Symp. Proc.
2:87), and at sites of inflammation such as the synovial fluid of
arthritic human joints (Catania et al. (1994) Neuroimmunomod.
1:321).
[0005] .alpha.-MSH and its carboxy terminal tripeptide act as in
vivo and in vitro regulators of inflammation (Cannon et al. (1986)
J Immunol. 137:2232; Robertson et al. (1986) Inflammation 10:371;
U.S. Pat. No. 5,028,592). The mode of action of .alpha.-MSH appears
to be via interference with NF-kB activation (Ichiyama et al.
(1999) J Neuroimmun. 99:211). In vivo administration of .alpha.-MSH
or the tripeptide .alpha.-MSH 11-13 inhibits LPS-mediated brain
inflammation by preventing inactivation of I-.kappa.B and
subsequent activation of NF-kB (Ichiyama et al. (1999) Brain Res.
836:31). NF-KB is a transcription factor that is necessary for the
transcription of proinflammatory cytokines, including .gamma.IFN
(Baeuerle et al. (1994) Ann Rev Immunol. 12:141).
SUMMARY OF THE INVENTION
[0006] The invention is based on the discovery that fusion
polypeptides containing .alpha.-MSH can be used to elicit a variety
of biological responses, in vitro and in vivo.
[0007] In one aspect, the invention features a polypeptide, or a
nucleic acid sequence encoding a polypeptide, wherein the
polypeptide contains an .alpha.-MSH concatamer. The polypeptide can
further include a trafficking sequence, e.g., a signal sequence. In
one embodiment, the signal sequence contains the
pro-opiomelanocortin (POMC) signal sequence or a portion thereof
that directs the secretion of the polypeptide when expressed in a
mammalian cell. Alternatively, the trafficking sequence can direct
the .alpha.-MSH concatamer to an endosome, nucleus, or a lysosome.
In another embodiment, the trafficking sequence can direct
secretion of the .alpha.-MSH concatamer.
[0008] A polypeptide containing an .alpha.-MSH concatamer can
further include a linker between two .alpha.-MSH units of the
.alpha.-MSH concatamer. The linker can optionally include a
protease cleavage site, e.g., a protease cleavage site specific for
a cell associated protease or a serum protease.
[0009] A polypeptide containing an .alpha.-MSH concatamer can
further include a membrane sequence. The membrane sequence can
include the membrane domain or a portion of the membrane domain of
a naturally occurring protein, e.g., a human protein, e.g., the
transferrin receptor. The polypeptide optionally includes a linker
between the .alpha.-MSH concatamer and the membrane sequence. The
linker can include a protease cleavage site. The polypeptide can
further include a signal sequence and/or a cytoplasmic domain.
[0010] A polypeptide containing an .alpha.-MSH concatamer can
further include a glycosylphosphatidylinositol (GPI) attachment
signal peptide. The polypeptide optionally includes a linker
between two .alpha.-MSH units of the .alpha.-MSH concatamer. The
linker can contain a protease cleavage site.
[0011] In one embodiment, a polypeptide containing an .alpha.-MSH
concatamer can further include a therapeutic polypeptide. Examples
of therapeutic polypeptides include .alpha.-gliadin, basement
membrane collagen, collagen, albumin, islet autoimmune antigen
(IAA), insulin, thyroid stimulating hormone (TSH) receptor,
thyroglobulin, voltage-gated potassium channels, glutamic acid
decarboxylase (GAD), insulin receptor, insulin associated antigen
(IA-w), heat shock protein (Hsp), synaptogamin in voltage-gated
calcium channels, myelin basic protein (MBP), proteolipid protein
(PLP), myelin oligodendrocyte-associated protein (MOG),
.alpha.B-crystallin, acetyl choline receptor, RNA-binding protein
HuD, PeV antigen complex, desmoglein (DG), dihydrolipoamide
acetyltransferase, pyruvate dehydrogenase complex 2 (PDC-E2), DNA
topoisomerase, RNA polymerase, immunoglobulin Fc, collagen,
topoisomerase I, interphotoreceptor retinoid-binding protein, and S
antigen (rod out segment).
[0012] In another aspect, the invention features a polypeptide, or
a nucleic acid sequence encoding a polypeptide, wherein the
polypeptide includes .alpha.-MSH and a membrane sequence. The
membrane sequence can include the membrane domain or a portion of
the membrane domain of a naturally occurring protein, e.g., a human
protein, e.g., the transferrin receptor. The polypeptide can
further include a linker between .alpha.-MSH and the membrane
sequence. The linker can contain a protease cleavage site.
[0013] A polypeptide containing .alpha.-MSH and a membrane sequence
can further include a signal sequence, a cytoplasmic domain, and/or
a therapeutic polypeptide, as described herein.
[0014] In another aspect, the invention features a polypeptide, or
a nucleic acid sequence encoding a polypeptide, wherein the
polypeptide includes .alpha.-MSH and a signal sequence. The signal
sequence can direct secretion of the polypeptide. In one
embodiment, the signal sequence contains the pro-opiomelanocortin
(POMC) signal sequence or a portion thereof that directs the
secretion of the polypeptide when expressed in a mammalian cell.
For example, the polypeptide can include the sequence
TABLE-US-00001 MPRSCCSRSGALLLALLLQASMEVRGWCLESSQCQD (SEQ ID NO:42)
LTTESNLLECIRACKPREGKRSYSMEHFRWGKPV,
MPRSCCSRSGALLLALLLQASMEVRGWCLESSQCQD (SEQ ID NO:47)
LTTESNLLECIRACKPREGKRSYSMEHFRWGKPVG,
MPRSCCSRSGALLLALLLQASMEVRGWCLESSQCQD (SEQ ID NO:49)
LTTESNLLECIRACKPREGKRSYSMEHFRWGKPVGK K,
MPRSCCSRSGALLLALLLQASMEVRGWCLESSQCQD (SEQ ID NO:51)
LTTESNLLECIRACKPREGKRSYSMEHFRWGKPVGK KR, or
MPRSCCSRSGALLLALLLQASMEVRGWCLESSQCQD (SEQ ID NO:78)
LTTESNLLECIRACKPREGKRSYSMEHFRWGKPVRS KR.
[0015] A polypeptide of the invention can further include a linker,
as described herein, between .alpha.-MSH and the signal sequence.
The polypeptide can include a secreted peptide, e.g., human or
murine serum albumin, or a portion thereof that directs secretion
of the polypeptide. For example, the polypeptide can include the
sequence TABLE-US-00002 MKWVTFISLLFLFSSAYSRGVFRRDAHKSEVAHRFK (SEQ
ID NO:59) DLGEENFKALVLIAFAQYLQQCPFEDHVKLVNEVTE
FAKTCVADESAENCDKSLHTLFGDKLCTVATLRETY
GEMADCCAKQEPERNECFLQHKDDNPNLPRLVRPEV
DVMCTAFHDNEETFLKKYLYEIARRHPYFYAPELLF
FAKRYKAAFTECCQAADKAACLLPKLDELRDEGKAS SAKGGYGGRIRRSYSMEHFRWGKPV,
MKWVTFISLLFLFSSAYSRGVFRRDAHKSEVAHRFK (SEQ ID NO:70)
DLGEENFKALVLIAFAQYLQQCPFEDHVKLVNEVTE
FAKTCVADESAENCDKSLHTLFGDKLCTVATLRETY
GEMADCCAKQEPERNECFLQHKDDNPNLPRLVRPEV
DVMCTAFHDNEETFLKKYLYEIARRHPYFYAPELLF
FAKRYKAAFTECCQAADKAACLLPKLDELRDEGKAS SAKGGYGGRIRRSYSMEHFRWGKPVG,
MKWVTFISLLFLFSSAYSRGVFRRDAHKSEVAHRFK (SEQ ID NO:71)
DLGEENFKALVLIAFAQYLQQCPFEDHVKLVNEVTE
FAKTCVADESAENCDKSLHTLFGDKLCTVATLRETY
GEMADCCAKQEPERNECFLQHKDDNPNLPRLVRPEV
DVMCTAFHDNEETFLKKYLYEIARRHPYFYAPELLF
FAKRYKAAFTECCQAADKAACLLPKLDELRDEGKAS SAKGGYGGRIRRSYSMEHFRWGKPVGKK,
MKWVTFISLLFLFSSAYSRGVFRRDAHKSEVAHRFK (SEQ ID NO:72)
DLGEENFKALVLIAFAQYLQQCPFEDHVKLVNEVTE
FAKTCVADESAENCDKSLHTLFGDKLCTVATLRETY
GEMADCCAKQEPERNECFLQHKDDNPNLPRLVRPEV
DVMCTAFHDNEETFLKKYLYEIARRHPYFYAPELLF
FAKRYKAAFTECCQAADKAACLLPKLDELRDEGKAS SAKGGYGGRIRRSYSMEHFRWGKPVGKKR,
MKWVTFISLLFLFSSAYSRGVFRRDAHKSEVAHRFK (SEQ ID NO:73)
DLGEENFKALVLIAFAQYLQQCPFEDHVKLVNEVTE
FAKTCVADESAENCDKSLHTLFGDKLCTVATLRETY
GEMADCCAKQEPERNECFLQHKDDNPNLPRLVRPEV
DVMCTAFHDNEETFLKKYLYEIARRHPYFYAPELLF
FAKRYKAAFTECCQAADKAACLLPKLDELRDEGKAS SAKGGYGGRIRRSYSMEHFRWGKPVRSKR,
MKWVTFISLLFLFSSAYSRGVFRRDAHKSEVAHRFK (SEQ ID NO:60)
DLGEENFKALVLIAFAQYLQQCPFEDHVKLVNEVTE
FAKTCVADESAENCDKSLHTLFGDKLCTVATLRETY
GEMADCCAKQEPERNECFLQHKDDNPNLPRLVRPEV
DVMCTAFHDNEETFLKKYLYEIARRHPYFYAPELLF
FAKRYKAAFTECCQAADKAACLLPKLDELRDEGKAS
SAKGGYGGRIRRSYSMEHFRWDEGKASSAKGGYGGR IRRSYSMEHFRWGKPV,
MKWVTFLLLLFVSGSAFSRGVFRREAHKSEIAHRYN (SEQ ID NO:61)
DLGEQHFKGLVLIAFSQYLQKCSYDEHAKLVQEVTD
FAKTCVADESAANCDKSLHTLFGDKLCAIPNLRENY
GELADCCTKQEPERNECFLQHKDDNPSLPPFERPEA
EAMCTSFKENPTTFMGHYLHEVARRHPYFYAPELLY
YAEQYNEILTQCCAEADKESCLTPKLDGVKEKALVS SVRGGYGGRIRRSYSMEHFRWGKPV,
MKWVTFLLLLFVSGSAFSRGVFRREAHKSEIAHRYN (SEQ ID NO:74)
DLGEQHFKGLVLIAFSQYLQKCSYDEHAKLVQEVTD
FAKTCVADESAANCDKSLHTLFGDKLCAIPNLRENY
GELADCCTKQEPERNECFLQHKDDNPSLPPFERPEA
EAMCTSFKENPTTFMGHYLHEVARRHPYFYAPELLY
YAEQYNEILTQCCAEADKESCLTPKLDGVKEKALV SSVRGGYGGRIRRSYSMEHFRWGKPVG,
MKWVTFLLLLFVSGSAFSRGVFRREAHKSEIAHRYN (SEQ ID NO:75)
DLGEQHFKGLVLIAFSQYLQKCSYDEHAKLVQEVTD
FAKTCVADESAANCDKSLHTLFGDKLCAIPNLRENY
GELADCCTKQEPERNECFLQHKDDNPSLPPFERPEA
EAMCTSFKENPTTFMGHYLHEVARRHPYFYAPELLY
YAEQYNEILTQCCAEADKESCLTPKLDGVKEKALVS SVRGGYGGRIRRSYSMEHFRWGKPVGKK,
MKWVTFLLLLFVSGSAFSRGVFRREAHKSEIAHRYN (SEQ ID NO:76)
DLGEQHFKGLVLIAFSQYLQKCSYDEHAKLVQEVTD
FAKTCVADESAANCDKSLHTLFGDKLCAIPNLRENY
GELADCCTKQEPERNECFLQHKDDNPSLPPFERPEA
EAMCTSFKENPTTFMGHYLHEVARRHPYFYAPELLY
YAEQYNEILTQCCAEADKESCLTPKLDGVKEKALVS SVRGGYGGRIRRSYSMEHFRWGKPVGKKR,
or MKWVTFLLLLFVSGSAFSRGVFRREAHKSEIAHRYN (SEQ ID NO:77)
DLGEQHFKGLVLIAFSQYLQKCSYDEHAKLVQEVTD
FAKTCVADESAANCDKSLHTLFGDKLCAIPNLRENY
GELADCCTKQEPERNECFLQHKDDNPSLPPFERPEA
EAMCTSFKENPTTFMGHYLHEVARRHPYFYAPELLY
YAEQYNEILTQCCAEADKESCLTPKLDGVKEKALVS
SVRGGYGGRIRRSYSMEHFRWGKPVRSKR.
The polypeptide can further include a therapeutic polypeptide
described herein.
[0016] In another aspect, the invention features a polypeptide, or
a nucleic acid sequence encoding a polypeptide, wherein the
polypeptide includes .alpha.-MSH and a GPI attachment signal
peptide. The polypeptide optionally includes a linker between
.alpha.-MSH and the GPI attachment signal peptide. The linker can
include, for example, a furin cleavage site. The polypeptide can
further include a therapeutic polypeptide.
[0017] The invention also features an expression vector encoding a
polypeptide as described herein. Examples of expression vectors
include a plasmid, a viral genome or portion thereof, and a
bacterial genome or portion thereof. Expression vectors also
include linear or circularized nucleic acids containing promoter
elements, .alpha.-MSH encoding units, and transcription terminators
with RNA processing signals (e.g. polyadenylation sequences).
[0018] The invention also features a method of making a
polypeptide. This method includes maintaining a cell containing an
expression vector containing a nucleic acid of the invention under
conditions permitting expression of the encoded polypeptide.
[0019] In another aspect, the invention features a method of
treatment including delivering a nucleic acid, polypeptide, or
analog as described herein to an individual, e.g., a mammal such as
a human or mouse, suffering from, or at risk of, a disorder of the
immune or nervous system. The method optionally includes a step
(prior to the delivery step) of identifying an individual as
suffering from, or at risk of, a disorder of the immune or nervous
system. In this method, the .alpha.-MSH composition preferably
mediates an immunomodulatory or neuro-modulatory function, e.g., an
anti-inflammatory function, when delivered to the individual.
[0020] The compositions of the invention can be used to effect a
wide variety of immunomodulatory functions, e.g., to inhibit the
activity of various cells and/or molecules of the immune system.
For example, the .alpha.-MSH compositions can be used to inhibit
histamine release from mast cells, neutrophil chemotaxis and/or
migration to an inflamed site, macrophage activation, or the
expression of costimulatory surface markers, e.g., CD86 and/or
CD40, by antigen presenting cells. The compositions may also induce
the secretion of TGF.beta. or IL-10 by cells.
[0021] In one example of a method of treatment, the individual has
an inflammatory disorder, e.g., rheumatoid arthritis, asthma,
sepsis, cirrhosis, dermatitis, psoriasis, contact hypersensitivity,
inflammatory bowel disease, or autoimmune encephalitis. In another
example, the individual has an autoimmune disorder, e.g., diabetes,
rheumatoid arthritis, multiple sclerosis, lupus, uveitis, or
coleiac disease. In another example, the individual is a candidate
for, or has received an organ transplant. In another example, the
individual is on chronic dialysis. In another example, the
individual has damage to neurons, e.g., spinal cord injury or
Alzheimer's disease. In another example the individual has obesity.
A nucleic acid or polypeptide can be delivered to the individual
via any of the following routes: pulmonary, intravenous (e.g.,
portal or tail vein), nasal, subcutaneous, intramuscular, rectal,
vaginal, intra-arterial (e.g., hepatic artery), transmucosal,
and/or oral.
[0022] In another aspect, the invention features a composition
containing a polypeptide including an .alpha.-MSH concatamer. This
composition can further include a membrane sequence, a signal
sequence, a GPI attachment signal peptide, and/or a therapeutic
compound, e.g., a therapeutic polypeptide. Other compositions of
the invention include: (1) an .alpha.-MSH containing peptide and a
membrane sequence; (2) an .alpha.-MSH containing peptide and a
signal sequence; and (3) an .alpha.-MSH containing peptide and a
GPI attachment signal peptide. Any of these compositions can
further include a therapeutic compound. The therapeutic compound
can be attached to the polypeptide, e.g., as a fusion polypeptide.
Alternatively, the therapeutic compound and polypeptide can be
mixed in a single composition, though not attached to each
other.
[0023] The invention also features a composition comprising a
delivery vehicle and a nucleic acid and/or polypeptide of the
invention. Examples of delivery vehicles include a depot, a
microparticle, a liposome, a suspension, a colloid, a dispersion, a
pellet, an implant, a pump, a particulate, a hydrogel, and an
Immune Stimulating Complex (ISCOM).
[0024] In another aspect, the invention includes a method of
generating regulatory T cells by providing a population of T cells
in vitro and mixing the population of T cells with an .alpha.-MSH
analog (or a cell expressing an .alpha.-MSH analog, or a nucleic
acid encoding an .alpha.-MSH analog) and a therapeutic compound,
e.g., an autoantigen. Any therapeutic compound as described herein
can be used in this method. According to this method, the mixing of
the population of T cells with an .alpha.-MSH analog and a
therapeutic compound results in the generation of regulatory T
cells in vitro. In one example, the .alpha.-MSH analog used in this
method is capable of binding to a melanocortin receptor expressed
on an antigen presenting cell. The .alpha.-MSH analog used in this
method can be a selective analog. For example, the .alpha.-MSH
analog may be unable to bind to or activate one or more
melanocortin receptors, e.g., an MC3-R receptor and/or an MC4-R
receptor. In one example, the .alpha.-MSH analog binds and
activates a single melanocortin receptor.
[0025] The regulatory T cells generated according to this method
can be introduced into an individual following their generation in
vitro. The source of the cell population used to generate the
regulatory T cells in vitro can either be from the same individual
receiving the treatment (autologous), a different individual of the
same species (allogeneic), or from an animal of a different species
(xenogeneic). In one example of this method, the individual suffers
from an autoimmune or inflammatory condition, and the
administration results in the improvement of one or more symptoms
of the condition.
[0026] Also included in the invention is a method of generating
regulatory T cells by administering to an individual an .alpha.-MSH
analog and a therapeutic compound. According to this method, the
administration results in the generation of regulatory T cells in
the individual. The .alpha.-MSH analog used in this method can be
capable of binding to a melanocortin receptor expressed on an
antigen presenting cell. The .alpha.-MSH analog used in this method
can be a selective analog. For example, the .alpha.-MSH analog may
be unable to bind to one or more melanocortin receptors, e.g., an
MC3-R receptor and/or an MC4-R receptor. In one example, the
.alpha.-MSH analog binds and activates a single melanocortin
receptor.
[0027] In one example, the individual suffers from an autoimmune or
inflammatory condition or is the recipient of an organ transplant,
and the administration results in the improvement or alleviation of
one or more symptoms of the condition.
[0028] Also included in the invention is a nucleic acid including a
sequence encoding a polypeptide including an .alpha.-MSH analog
concatamer. The polypeptide can include two or more .alpha.-MSH
analogs or an .alpha.-MSH analog and an .alpha.-MSH.
[0029] Also included in the invention is a nucleic acid including a
sequence encoding a polypeptide including an .alpha.-MSH analog and
a membrane sequence. The invention also includes a nucleic acid
including a sequence encoding a polypeptide including an
.alpha.-MSH analog and a trafficking sequence such as a signal
sequence. In one embodiment, the signal sequence contains the
pro-opiomelanocortin (POMC) signal sequence or a portion thereof
that directs the secretion of the polypeptide when expressed in a
mammalian cell. Also included in the invention is a nucleic acid
including a sequence encoding a polypeptide including an
.alpha.-MSH analog and a GPI attachment signal peptide.
[0030] In another aspect, the invention includes a method of
treatment including delivering a therapeutic compound (or a nucleic
acid encoding a therapeutic compound) and an .alpha.-MSH-containing
polypeptide (or a nucleic acid encoding an .alpha.-MSH-containing
polypeptide) to an individual suffering from, or at risk of
contracting, a disorder of the immune system. The disorder can be
an autoimmune disorder, e.g., multiple sclerosis. The therapeutic
compound can be contained in a composition that is administered to
an individual to treat the disorder of the immune system. For
example, the therapeutic compound can be contained within an
interferon beta-containing composition. In this example,
administration of the interferon beta-containing composition can
cause an adverse local reaction in the treated individual. The
method can include an additional step of identifying an individual
as having, or being at risk of having, a disorder of the immune
system, e.g., an autoimmune disorder such as multiple sclerosis.
The .alpha.-MSH-containing polypeptide (or nucleic acid encoding an
.alpha.-MSH-containing polypeptide) can optionally include an
.alpha.-MSH analog in place of or in addition to the .alpha.-MSH
amino acid sequence.
[0031] Unless otherwise defined, all technical and scientific terms
used herein have the same meaning as commonly understood by one of
ordinary skill in the art to which this invention belongs. Although
methods and materials similar or equivalent to those described
herein can be used in the practice or testing of the present
invention, the preferred methods and materials are described below.
All publications, patent applications, patents, and other
references mentioned herein are incorporated by reference in their
entirety. In case of conflict, the present application, including
definitions, will control. The materials, methods, and examples are
illustrative only and not intended to be limiting.
[0032] Other features and advantages of the invention will be
apparent from the following detailed description, and from the
claims.
BRIEF DESCRIPTION OF THE DRAWINGS
[0033] FIG. 1A depicts the structure of the POMC polypeptide, with
the various regions indicated below the polypeptide by reference to
their amino acid positions.
[0034] FIG. 1B depicts the structure of the miniPOMC
polypeptide.
[0035] FIG. 2A depicts the nucleotide (SEQ ID NO:43) and amino acid
(SEQ ID NO:42) sequences of the miniPOMC construct. The .alpha.-MSH
sequence is underlined in this figure.
[0036] FIG. 2B depicts the nucleotide (SEQ ID NO:46) and amino acid
(SEQ ID NO:47) sequences for an ACTH(1-14) construct. The
ACTH(1-14) sequence is underlined in this figure.
[0037] FIG. 2C depicts the nucleotide (SEQ ID NO:48) and amino acid
(SEQ ID NO:49) sequences for an ACTH (1-16) construct. The
ACTH(1-16) sequence is underlined in this figure.
[0038] FIG. 2D depicts the nucleotide (SEQ ID NO:50) and amino acid
(SEQ ID NO:51) sequences for an ACTH(1-17) construct. The
ACTH(1-17) sequence is underlined in this figure.
[0039] FIG. 2E depicts the nucleotide (SEQ ID NO:79) and amino acid
(SEQ ID NO:78) sequences for an .alpha.MSH-f construct. The
.alpha.MSH-f sequence is underlined in this figure.
[0040] FIG. 3 depicts the expression vector pZYC-ssMSH.
[0041] FIG. 4 depicts the structure of .alpha.-MSH/serum albumin
fusion polypeptides. The arrows indicate sites of the polypeptide
subject to cleavage by a protease.
[0042] FIG. 5 depicts melanin synthesis, as measured by absorbance
readings at 405 nm, by untransfected B16/F10 cells treated with
supeematant produced by B16/F10 cells transfected with: (1) mock
transfection (no vector); (2) pCMV-Script control vector; (3)
pCMV-miniPOMC; (4) pZYC-miniPOMC; (5) pCMV-miniPOMC; or (6)
pIRES-2X miniPOMC.
[0043] FIG. 6 depicts melanin synthesis, as measured by absorbance
readings at 405 nm, by B16/F10 cells to which various
concentrations of alpha-MSH peptide have been added.
[0044] FIG. 7 depicts melanin synthesis, as measured by absorbance
readings at 405 nm, by untransfected B16/F10 cells treated with
supernatant produced by B16/F10 cells transfected with: (1)
pCMV-Script control vector; (2) pCMV-miniPOMC; (3) pCMV-ACTH(1-14);
(4) pCMV-ACTH(1-16); or (5) pCMV-ACTH(1-17).
[0045] FIG. 8 depicts the results of a radioimmunoassay (RIA) that
detects .alpha.-MSH in the supernatant of cells transfected with
the following constructs: (1) mock transfected cells; (2)
pCMV-Script control vector; (3) pCMV-miniPOMC; (4) pCMV-ACTH(1-14);
(5) pCMV-ACTH(1-16); or (6) pCMV-ACTH(1-17).
[0046] FIG. 9 depicts melanin synthesis (pg/ml) by untransfected
B16/F10 cells treated with supernatant produced by B16/F10 cells
transfected with: (1) pCMV-ssMSH; (2) pZYC-ssMSH; or (3)
pIRES-2X-ssMSH.
[0047] FIG. 10 depicts melanin synthesis (pg/ml) by untransfected
B16/F10 cells treated with supernatant produced by B16/F10 cells
transfected with: (1) SH195 human serum albumin control vector; (2)
SM195 mouse serum albumin control vector; (3) HLF.alpha. vector; or
(4) MLF.alpha. vector.
[0048] FIGS. 11A and 11B depict melanin synthesis, as measured by
absorbance readings at 405 nm, by untransfected B16/F10 cells
treated with sera from mice injected intradermally (FIG. 11A) or
intravenously (FIG. 11B) with miniPOMC-encoding expression
vectors.
[0049] FIG. 12 depicts the activity level of NF-kB in HeLa cells
transfected with .alpha.-MSH expressing constructs. For each
construct, luciferase activity was measured relative to vector
controls.
[0050] FIGS. 13A and 13B depict the activity level of NF-kB in RAW
264.7 mouse macrophage cells transfected with .alpha.-MSH
expressing constructs. For each construct, luciferase activity was
measured relative to vector controls.
[0051] FIG. 14 depicts the activation of NF-kB in Sol8 mouse muscle
cells transfected with .alpha.-MSH expressing constructs. For each
construct, luciferase activity was measured relative to vector
controls.
[0052] FIG. 15A depicts the results of a direct binding assay used
to detect NF-kB activation in RAW 264.7 mouse macrophage and HeLa
cells transfected with pZYC-ssMSH as compared to a control
vector.
[0053] FIG. 15B depicts the results of a direct binding assay used
to detect NF-kB activation in RAW 264.7 mouse macrophage
transfected with pCMV empty vector, pCMV-ACTH(1-14),
pCMV-ACTH(1-16), or pCMV-ACTH(1-17).
[0054] FIG. 16A depicts the results of three separate experiments
in which an .alpha.-MSH peptide was used to treat Experimental
Autoimmune Encephalitis (EAE).
[0055] FIG. 16B depicts the depicts the mean accumulated EAE
clinical score in mice treated with an .alpha.-MSH encoding nucleic
acid.
[0056] FIG. 16C depicts the mean day of the onset of EAE clinical
symptoms in mice treated with an .alpha.-MSH encoding nucleic
acid.
[0057] FIG. 17A depicts the results of an experiment in which an
.alpha.-MSH analog was used to treat Inflammatory Bowel Disease
(IBD).
[0058] FIG. 17B depicts the results of an experiment in which a
miniPOMC vector was used to treat IBD.
[0059] FIG. 18A depicts the results of an experiment in which an
.alpha.-MSH analog was used to treat obesity.
[0060] FIG. 18B depicts the results of an experiment in which a
miniPOMC vector was used to treat obesity.
DETAILED DESCRIPTION
[0061] The invention encompasses compositions and methods for the
in vivo and in vitro delivery of polypeptides containing
.alpha.-MSH, CL-MSH analogs, and nucleic acids encoding .alpha.-MSH
and/or .alpha.-MSH analogs.
Polypeptides
[0062] Polypeptides of the invention include an .alpha.-MSH peptide
fused to additional amino acid sequences. As used herein,
".alpha.-MSH" refers to a peptide of which the amino acid sequence
is SYSMEHFRWGKPV (SEQ ID NO:1) or a fragment thereof that binds to
a melanocortin receptor, e.g., MC1-R, with a binding affinity of at
least 50% of that possessed by the SYSMEHFRWGKPV (SEQ ID NO:1)
peptide. Preferably, the .alpha.-MSH peptide includes the amino
acid sequence KPV (SEQ ID NO:2) or EHFRW (SEQ ID NO:41).
Polypeptides of the invention can, for example, include any of the
following sequences: SYSMEHFRWGKPV (SEQ ID NO:1); SYSMEHFRWGKPVG
(SEQ ID NO:62); SYSMEHFRWGKPVGKK (SEQ ID NO:63); SYSMEHFRWGKPVGKKR
(SEQ ID NO:64); or SYSMEHFRWGKPVRSKR (SEQ ID NO:69). An .alpha.-MSH
containing peptide can be N-terminal acetylated and/or C-terminal
amidated.
[0063] In one embodiment, the polypeptide induces the generation of
regulatory T cells, either in vitro or in vivo. In another
embodiment, the polypeptide causes weight reduction in a subject
having an obese phenotype, e.g., POMC or leptin deficient mice. In
another embodiment, the polypeptide possesses at least 50% of an
anti-inflammatory activity of the SYSMEHFRWGKPV (SEQ ID NO: 1)
peptide, as reviewed in Lipton and Catania (1997) Immunol. Today
18:140-145, herein incorporated by reference. Examples of
anti-inflammatory activities of the SYSMEHFRWGKPV (SEQ ID NO:1)
peptide include: (1) inhibition of hepatic nitric oxide and
leukocyte infiltration in mice pretreated with Corynebacterium
parvum followed by an acute injection of lipopolysaccharide (LPS);
(2) inhibition of the development of chronic inflammation in
mycobacterium-induced rats; (3) improvements of aspects of systemic
inflammatory-response syndrome; (4) decreased histamine release by
mast cells; (5) decreased neutrophil migration; and (6) decreased
macrophage and dendritic cell activation, as measured by cytokine
release or expression of a cell surface marker. In another
embodiment, the polypeptide has one or more of the following
activities: (1) the ability to reduce the activity of NF-kB
(methods of evaluating NF-kB activation are described in Example
5); (2) the ability to increase melanin production by melanocytes
(methods of evaluating melanin synthesis are described in Example
3); or (3) the ability to increase cAMP levels in a cell expressing
a melanocortin receptor.
[0064] .alpha.-MSH fusion polypeptides can be produced by
recombinant DNA techniques, chemical coupling, or chemical
synthesis. As used herein, "fusion polypeptide" refers to a
polypeptide that does not correspond to the amino acid sequence of
a naturally occurring protein or fragment thereof. Fusion
polypeptides including an .alpha.-MSH fused to additional peptide
sequences can take many forms, as described below.
[0065] A polypeptide can include an .alpha.-MSH concatamer. An
".alpha.-MSH concatamer" is a polypeptide containing two or more
.alpha.-MSH peptides. The .alpha.-MSH units of the concatamer may
optionally include additional amino acid sequences between the
units and/or flanking the units. This arrangement of .alpha.-MSH
peptides can include any number of .alpha.-MSH units, e.g., at
least 2, 3, 4, 5, 10, 20, 30, 40, 50, 100, 200, or more .alpha.-MSH
units.
[0066] The .alpha.-MSH units of an .alpha.-MSH concatamer can be
separated by a linker sequence. The linker sequence need not be of
any defined length. A linker sequence separating .alpha.-MSH units
can include an amino acid sequence that functions as a protease
cleavage site (an amino acid sequence that can be specifically
recognized and cleaved by a protease). For example, an .alpha.-MSH
concatamer containing five .alpha.-MSH units, each unit linked to
another by a linker sequence comprising a protease cleavage site,
can be cleaved by a protease to release five individual .alpha.-MSH
units, with or without leftover linker residues at one end or the
other. Additionally, some of the linkers may not comprise a
protease cleavage site, resulting in one or more intact .alpha.-MSH
concatamers following protease cleavage. The linker sequence
between two .alpha.-MSH units can optionally contain two or more
protease cleavage sites. For example, the linker can include a
protease cleavage site that cleaves immediately adjacent to the
carboxy end of a first .alpha.-MSH unit, followed by a stretch of
amino acids, followed by another protease cleavage that cleaves
immediately adjacent to the amino end of a second .alpha.-MSH unit.
This results in the release of .alpha.-MSH units having few if any
linker amino acids remaining attached to the .alpha.-MSH
sequence.
[0067] The protease cleavage site can be a site recognized, for
example, by a cell-associated protease or a serum protease. Cell
associated proteases include membrane proteins, membrane-associated
proteins, and cytosolic proteins. An example of a protease cleavage
site recognized by a cell-associated protease is the amino acid
sequence recognized by furin, a cell-associated protease found in
the trans golgi.
[0068] As an alternative (or in addition) to facilitating
protease-induced cleavage, the linker sequence can provide spacing
and/or orientation to the respective .alpha.-MSH units that promote
the biological functioning of the individual .alpha.-MSH units in
the context of an intact .alpha.-MSH concatamer. In this context,
the linker sequence should separate the .alpha.-MSH units by a
distance sufficient to ensure that each .alpha.-MSH unit properly
folds into its secondary structure. Preferred linker sequences of
this variety (1) should adopt a flexible extended conformation, (2)
should not exhibit a propensity for developing an ordered secondary
structure that could interact with the functional .alpha.-MSH
units, and (3) should have minimal hydrophobic or charged
character, which could promote undesired interaction with the
functional .alpha.-MSH units. Typical surface amino acids in
flexible protein regions include Gly, Asn and/or Ser. Permutations
of amino acid sequences containing Gly, Asn and Ser would be
expected to satisfy the above criteria for a linker sequence. Other
near-neutral amino acids, such as Thr and Ala, can also be used in
the linker sequence.
[0069] A linker sequence length of 20 amino acids can be used to
provide a suitable separation of functional protein domains,
although longer or shorter linker sequences may also be used. The
length of the linker sequence separating the .alpha.-MSH units is
generally greater than 3, and preferably greater than 4 amino
acids: for example, from 5 to 500 amino acids, or more preferably
from 5 to 100 amino acids Preferably, the linker sequence is from
about 5-30 amino acids. In preferred embodiments, the linker
sequence is about 5 to about 20 amino acids, or about 10 to about
20 amino acids. Amino acid sequences useful as linkers of the
.alpha.-MSH units include, but are not limited to, (SerGly.sub.4;
SEQ ID NO:65)y wherein y is at least 2, or Gly.sub.4SerGly.sub.5Ser
(SEQ ID NO:66). A preferred linker sequence has the formula
(SerGly.sub.4).sub.4 (SEQ ID NO:67). Another preferred linker has
the sequence ((Ser.sub.4Gly).sub.3SerPro) (SEQ ID NO:68).
[0070] Alternatively, the .alpha.-MSH units can be directly fused
without a linker.
[0071] A polypeptide including an .alpha.-MSH concatamer can
further include a trafficking sequence. A "trafficking sequence" is
an amino acid sequence that causes a polypeptide to which it is
fused to be transported to a specific compartment of the cell
and/or to be secreted by the cell. As defined herein, the term
"trafficking sequence" is used interchangeably with "targeting
sequence". The trafficking sequence can be included in the fusion
polypeptide in the presence or absence of a linker sequence between
.alpha.-MSH units and/or between the trafficking sequence and an
.alpha.-MSH unit.
[0072] A signal sequence, a particular type of trafficking
sequence, can fused to the .alpha.-MSH concatamer. A "signal
sequence" is a peptide sequence that interacts with a signal
recognition particle and directs a ribosome to the endoplasmic
reticulum (ER) during translation. A signal sequence results in the
protein of which it a component either being secreted or targeted
to a membrane. The signal sequence is cleaved from the polypeptide
in the ER, resulting in the mature form of the protein, e.g., a
secreted protein. An example of a useful signal sequence that can
be fused to the .alpha.-MSH concatamer is the signal sequence of
the POMC polypeptide (MPRSCCSRSGALLLALLLQASMEVRG; SEQ ID NO:3) or a
portion thereof that directs the secretion of the polypeptide when
expressed in a mammalian cell. Preferably, the portion of the POMC
signal sequence includes a fragment of the POMC signal sequence at
least five amino acids in length. Other useful signal sequences
include the signal peptide of HLA-DRa (MAISGVPVLGFFIIAVLMSAQESWA;
SEQ ID NO:4) and the signal peptides of the Adenovirus E3 and E1a
proteins.
[0073] The trafficking sequence, e.g., a signal sequence, can
include the sequence of a secreted peptide, e.g., serum albumin,
e.g., human or murine serum albumin, or a portion thereof that
directs secretion of the polypeptide.
[0074] Other examples of trafficking sequences that can be fused to
the .alpha.-MSH concatamer include an amino acid sequence that
guides a polypeptide to an endosome (e.g., the trafficking sequence
of the invariant chain), a secretory granule (e.g., the POMC
sorting sequence (WCLESSQCQDLTTESNLLECIRACKP; SEQ ID NO:5)), and a
lysosome (e.g., KFERQ (SEQ ID NO:6), QREFK (SEQ ID NO:7), and other
pentapeptides having Q flanked on one side by four residues
selected from K, R, D, E, F, I, V, and L).
[0075] A polypeptide containing an .alpha.-MSH concatamer can
further include a membrane sequence. A "membrane sequence" of the
fusion polypeptide can be any sequence that can be anchored in a
membrane, thereby maintaining the membrane attachment of the
polypeptide of which the membrane sequence is a component. A
membrane sequence includes a sequence of at least about 15 amino
acid residues, e.g., about 20, 25, 30, 35, 40, or 45 residues,
which are inserted in the membrane. The membrane sequence can
optionally span the membrane. Membrane sequences are rich in
hydrophobic residues, and typically have an alpha-helical
structure. In a preferred embodiment, at least 50%, e.g., at least
60%, 70%, 80%, 90%, 95% or even all of the amino acids of a
membrane domain are hydrophobic, e.g., leucines, isoleucines,
tyrosines, or tryptophans. Membrane domains are described in, for
example, Zagotta et al. (1996) Annual Rev. Neurosci. 19: 235-263.
The membrane sequence can correspond to all or a portion of the
membrane domain of a naturally occurring protein, e.g., a human
protein, e.g., the membrane domain of the transferrin receptor. A
"portion of a membrane domain" means a sequence of consecutive
amino acids contained in the membrane domain of a naturally
occurring protein, wherein the portion retains the ability to
maintain the polypeptide of which it is a component anchored in or
associated with the cell membrane. Alternatively, the membrane
sequence can be a variant of a naturally occurring membrane domain
(i.e., with one or more substituted residues) or portion thereof,
or can be a completely artificial amino acid sequence.
[0076] Polypeptides including an .alpha.-MSH concatamer can
optionally contain a stretch of hydrophobic amino acids at its
amino terminus that functions as an uncleaved signal for
translocation into the endoplasmic reticulum and anchoring of the
protein in the membrane, e.g., the hydrophobic transmembrane
domains of type II transmembrane proteins such as the invariant
chain (Ii), Ly-49, CD23, CD69, hepatic lectins, influenza virus
neuraminidase, and intestinal isomaltase.
[0077] When inserted into the plasma membrane, the .alpha.-MSH
concatamer can be oriented either extracellularly or
intracellularly. Alternatively, the polypeptide can include one or
more .alpha.-MSH units on either side of the membrane domain, so
that the resultant polypeptide can have extracellular and
intracellular .alpha.-MSH units.
[0078] The polypeptide can include a linker sequence between the
membrane sequence and an .alpha.-MSH unit, a linker sequence
between .alpha.-MSH units, or both. A linker sequence can include
an amino acid sequence that functions as a protease cleavage site,
as described herein. Alternatively, the linker sequence can be
designed to orient the .alpha.-MSH units in a manner that promotes
their biological activity.
[0079] Polypeptides including an .alpha.-MSH concatamer linked to a
membrane sequence can further include a cytoplasmic domain. A
"cytoplasmic domain" refers to a portion of a polypeptide described
herein that is located in the cytoplasm when the polypeptide is
inserted in a membrane, e.g., a plasma membrane. The cytoplasmic
domain can be of any length and can be derived from a naturally
occurring protein or can be an artificial sequence. A cytoplasmic
domain can control the regulation or sorting of the polypeptide.
For example, the cytoplasmic domain of the invariant chain (Ii)
contains sequences that cause sorting of Ii to an endosome. Other
cytoplasmic domains can participate in cell signaling
processes.
[0080] A polypeptide containing an .alpha.-MSH concatamer can
further include a glycosylphosphatidylinositol (GPI) attachment
signal peptide. A "GPI attachment signal peptide" refers to an
amino acid sequence that directs replacement of itself by a
preassembled GPI in the ER. The GPI attachment signal peptide at
the carboxy terminus of a GPI-linked protein is replaced by a
preassembled GPI in the ER by a transamidation reaction, through
the formation of a carbonyl intermediate. Many eukaryotic cell
surface proteins are anchored to the cell membrane via a GPI
linkage. The GPI attachment signal peptides of Thy-1 (see
GenBank.TM. Accession Number P04216) and CD24 (see GenBank.TM.
Accession Number A48996) are examples of GPI attachment signal
peptides that may optionally be linked to the .alpha.-MSH
concatamer described herein.
[0081] Anchoring a polypeptide to the membrane via linkage to GPI
permits cleavage of the polypeptide from the membrane by
phosphatidylinositol-specific phospholipases. For example, when a
cell containing, attached to its plasma membrane, an .alpha.-MSH
concatamer fused to a GPI moiety is treated with
phosphatidylinositol-specific phospholipase C (PI-PLC), cleavage
and release of the .alpha.-MSH concatamer will occur. The
polypeptide can also contain a linker sequence between .alpha.-MSH
units of the concatamer and/or between the GPI moiety and the
.alpha.-MSH concatamer. A linker sequence can include an amino acid
sequence that functions as a protease cleavage site, as described
herein. For example, a polypeptide can include five .alpha.-MSH
units linked to each other by a linker comprising a protease
cleavage site, wherein the carboxy terminal .alpha.-MSH unit is
fused to a GPI attachment signal peptide.
[0082] In another aspect of the invention, a polypeptide can
include .alpha.-MSH fused to a membrane sequence. This polypeptide
can include a single .alpha.-MSH, rather than the multiple units
contained in the .alpha.-MSH concatamer described above. This
polypeptide can for example have a length of less than 45 amino
acids (e.g., less than 40, 35, 30, 25, or 20). This
.alpha.-MSH-membrane sequence fusion can have any of the properties
described above for the fusion of an .alpha.-MSH concatamer and a
membrane sequence. For example, the .alpha.-MSH membrane sequence
fusion polypeptide can further include a signal sequence or other
trafficking sequence. Additionally, the fusion polypeptide can
include a linker sequence, e.g., located between the membrane
sequence and .alpha.-MSH. This linker sequence can include an amino
acid sequence that can function as a protease cleavage site.
[0083] In another aspect of the invention, a polypeptide can also
include .alpha.-MSH and a trafficking sequence. This polypeptide
can include a single .alpha.-MSH, rather than the multiple units
contained in the .alpha.-MSH concatamer described above. This
trafficking sequence can have any of the properties described above
for the fusion of an .alpha.-MSH concatamer and a trafficking
sequence. In one example, the trafficking sequence is not the POMC
signal sequence. If the trafficking sequence is the POMC signal
sequence, then the fusion polypeptide preferably does not include
the entire POMC sequence, and most preferably contains (a) the POMC
signal sequence, (b) the POMC sorting sequence, (c) an .alpha.-MSH
containing peptide, and (d) optionally a partial junction peptide
of POMC containing protease digestion sites. Examples of such a
fusion polypeptide include: TABLE-US-00003
MPRSCCSRSGALLLALLLQASMEVRGWCLESSQCQD (SEQ ID NO:42)
LTTESNLLECIRACKPREGKRSYSMEHFRWGKPV;
MPRSCCSRSGALLLALLLQASMEVRGWCLESSQCQD (SEQ ID NO:47)
LTTESNLLECIRACKPREGKRSYSMEHFRWGKPVG;
MPRSCCSRSGALLLALLLQASMEVRGWCLESSQCQD (SEQ ID NO:49)
LTTESNLLECIRACKPREGKRSYSMEHFRWGKPVGK K;
MPRSCCSRSGALLLALLLQASMEVRGWCLESSQCQD (SEQ ID NO:51)
LTTESNLLECIRACKPREGKRSYSMEHFRWGKPVGK KR; and
MPRSCCSRSGALLLALLLQASMEVRGWCLESSQCQD (SEQ ID NO:78)
LTTESNLLECIRACKPREGKRSYSMEHFRWGKPVRS KR.
[0084] The trafficking sequence, e.g., a signal sequence, can
correspond to the sequence of a secreted peptide, e.g., serum
albumin, e.g., human or murine serum albumin, or a portion thereof
that directs secretion of the polypeptide. The fusion polypeptide
can have a length of less than 100 amino acids, such as less than
90, 80, 70, 60, 50, 40, 30, or 20 amino acids. The fusion
polypeptide can include a linker sequence, e.g., located between
the trafficking sequence and .alpha.-MSH. In one example, a fusion
polypeptide contains an albumin sequence or a portion thereof that
promotes secretion of the polypeptide, a linker sequence, e.g.,
GGVGG (SEQ ID NO:44) or GGYGG (SEQ ID NO:57), and an .alpha.-MSH
containing peptide, e.g., SYSMEHFRWGKPV (SEQ ID NO:1),
SYSMEHFRWGKPVG (SEQ ID NO:62), SYSMEHFRWGKPVGKK (SEQ ID NO:63),
SYSMEHFRWGKPVGKKR (SEQ ID NO:64), or SYSMEHFRWGKPVRSKR (SEQ ID
NO:69). A linker sequence can optionally include an amino acid
sequence that can function as a protease cleavage site. In one
example, the fusion polypeptide contains: (a) mouse serum albumin
signal peptide; (b) mouse serum albumin signal propeptide; (c)
mouse serum albumin; (d) an .alpha.-MSH containing peptide; and (e)
optionally an amino acid sequence that functions as linker and
protease cleavage sites between (c) and (d) The protease cleavage
site can be a furin cleavage site. In addition, human serum albumin
signal peptide, human serum albumin signal propeptide, and human
serum albumin can be used.
[0085] In a polypeptide that includes a trafficking sequence, e.g.,
a signal sequence, and .alpha.-MSH, the .alpha.-MSH need not be
directly linked to the trafficking sequence. As described above,
the trafficking sequence and the .alpha.-MSH can be separated by a
linker. Additionally, the .alpha.-MSH can be inserted, e.g., by
recombinant DNA technology, within all or a portion of the amino
acid sequence of a secreted protein, e.g., a secreted protein
having a signal sequence. Preferably, the .alpha.-MSH is positioned
in the fusion polypeptide in what corresponds to an exposed portion
of the secreted protein, such as a solvent accessible loop of the
secreted protein, e.g., the .alpha.-MSH is not inserted in a
portion of the amino acid sequence of the secreted protein that is
buried such as an a helix or a .beta. pleated sheet. The fusion
polypeptide can optionally include protease cleavage sites that
flank the .alpha.-MSH peptide to promote cleavage of .alpha.-MSH
from the fusion polypeptide.
[0086] Many fusion polypeptides can be made between a serum albumin
or a fragment thereof and an .alpha.-MSH peptide. For example,
.alpha.-MSH can be fused to the carboxy terminus of murine or human
serum albumin. A linker can be included between the serum albumin
sequence and the .alpha.-MSH sequence. The linker can include a
protease recognition site such as a furin cleavage site. In another
example, .alpha.-MSH can be inserted in a solvent accessible loop
of albumin, e.g., human or murine serum albumin. The
three-dimensional structure of serum albumin demonstrates that the
protein contains at least four solvent accessible loops.
.alpha.-MSH sequences could be placed in one, two, three, or four
of these loops. The resulting fusion polypeptide can be used as a
source of biologically active .alpha.-MSH. The fusion polypeptide
can optionally include protease cleavage sites that flank the
.alpha.-MSH sequences. In this way, a single fusion protein can be
used to enhance the number of .alpha.-MSH molecules that can be
produced.
[0087] In another aspect of the invention, a polypeptide can also
include .alpha.-MSH fused to a GPI attachment signal peptide. This
polypeptide can include a single .alpha.-MSH, rather than the
multiple units contained in the .alpha.-MSH concatamer described
above. The GPI attachment signal peptide can have any of the
properties describe above for the fusion of an .alpha.-MSH
concatamer and a GPI attachment signal peptide. The polypeptide can
include a linker sequence, e.g., a sequence comprising a protease
cleavage site, between .alpha.-MSH and the GPI attachment signal
peptide. Alternatively, the polypeptide can include a linker
without a protease cleavage site or no linker at all between
.alpha.-MSH and the GPI attachment signal peptide. In this
embodiment, .alpha.-MSH can be cleaved from the cell membrane by
the action of, e.g., PI-PLC.
[0088] The .alpha.-MSH containing compositions described herein can
include a therapeutic compound. A "therapeutic compound" is a
compound that is causally associated with the occurrence of an
immunologic reaction, e.g., inflammation or autoimmunity, and/or a
neural condition in a mammal. A therapeutic compound can be a
"therapeutic polypeptide," defined herein as a polypeptide or
fragment thereof that is causally associated with occurrence of an
immunologic reaction, e.g., inflammation or autoimmunity, and/or a
neural condition in a mammal. Additionally, the therapeutic
compound can be a non-peptide compound, e.g., single or double
stranded DNA (dsDNA), a lipid, single or double stranded RNA
(dsRNA), a carbohydrate, or a small molecule.
[0089] A composition containing a therapeutic compound (or a
nucleic acid encoding a therapeutic compound) includes either an
.alpha.-MSH-containing polypeptide or a nucleic acid encoding an
.alpha.-MSH-containing polypeptide. A therapeutic compound can
either be physically associated with an .alpha.-MSH-containing
polypeptide, e.g., fused or conjugated as described herein, or a
therapeutic compound and an .alpha.-MSH-containing polypeptide can
be contained within the same container, though not physically
associated.
[0090] A compound can be designated a "therapeutic compound" on the
basis of its causing an adverse immunologic reaction when
administered to an individual. For example, interferon beta (e.g.,
interferon beta-1a or interferon beta-1b)-containing compositions
can cause adverse local reactions, e.g., skin reactions, when
administered to an individual having multiple sclerosis. Therefore,
an interferon beta-containing composition contains a therapeutic
compound, as the-term is used herein. A composition of the
invention can thus include: (1) an .alpha.-MSH-containing
polypeptide or a nucleic acid encoding an .alpha.-MSH-containing
polypeptide; and (2) an interferon beta-containing composition.
[0091] A therapeutic polypeptide can include a peptide epitope that
can be presented by a MHC class I or class II molecule of the
mammal that exhibits the inflammation and/or autoimmunity. The
therapeutic polypeptide can be self or nonself. For example, the
therapeutic polypeptide can be an "autoantigen," defined herein a
self polypeptide or antigenic fragment thereof that is causally
associated with occurrence of an autoimmune disease in a mammal
that produces the self polypeptide. An autoantigen can include a
peptide epitope that can be presented by a MHC class I or class II
molecule of the mammal that exhibits the autoimmunity.
[0092] A therapeutic compound can be fused to any of the
.alpha.-MSH polypeptides of the invention. The therapeutic compound
can be fused to an .alpha.-MSH polypeptide either by recombinant
DNA techniques, chemical coupling, or chemical synthesis. For
example, a polypeptide can include a signal sequence, .alpha.-MSH
or an .alpha.-MSH concatamer, and a therapeutic compound.
Optionally, a linker, e.g., a linker including a protease cleavage
site, can separate the therapeutic compound and .alpha.-MSH. The
therapeutic compound-.alpha.-MSH fusion can include any of the
other polypeptide features described herein: a membrane sequence, a
signal sequence, a linker, and/or a GPI attachment signal
peptide.
[0093] Examples of therapeutic compounds that can be used are
listed in Table 1. When .alpha.-MSH is produced within an animal by
expression of a nucleic acid described herein, the polypeptide can
trigger IL-10 production and thereby activate regulatory T cells.
The production of both .alpha.-MSH and a therapeutic polypeptide in
the cell of a mammal, e.g., an antigen presenting cell (APC), are
expected to generate regulatory T cells specific for the expressed
therapeutic polypeptide (see, e.g., Nishida and Taylor (1999)
Invest. Opthamol. Vis. Sci. 40:2268-74). These regulatory T cells
would then home to the site of antigen expression in the periphery
(e.g., the pancreas for diabetes or the joint for arthritis) and
modulate the activity of the disease-inducing T cell population, to
prevent or improve the disease symptoms.
[0094] A therapeutic polypeptide can include an MHC-binding
peptide. The MHC-binding peptide can affect T cell function by
tolerizing or anergizing a T cell. Alternatively, the MHC-binding
peptide could be designed to modulate T cell function by altering
cytokine secretion profiles following recognition of the
MHC/peptide complex. Peptides recognized by T cells can induce
secretion of cytokines that (a) cause B cells to produce antibodies
of a particular class, (b) induce inflammation, and (c) further
promote host T cell responses.
[0095] Examples of therapeutic polypeptides include fragments of
myelin basic protein (MBP), proteolipid protein (PLP), GAD65, islet
cell antigen, collagen, desmoglein, .alpha.-crystallin, or
.beta.-crystallin, wherein the fragment can bind an MHC class I or
II molecule. Table 1 lists many therapeutic compounds that are
thought to be involved in autoimmune disease, such as multiple
sclerosis, diabetes, uveitis, rheumatoid arthritis, and myasthenia
gravis. Fragments of protein antigens can be essentially identical
to any of the peptides listed in Table 2, such as MBP residues
80-102 (SEQ ID NO:8) or PLP residues 170-191 (SEQ ID NO:9).
TABLE-US-00004 TABLE 1 Therapeutic Compounds Disease Associated
Antigen References Coeliac disease .alpha.-Gliadin a Goodpasture's
syndrome Basement membrane collagen a Graves' disease Thyroid
Stimulating Hormone (TSH) a receptor Hashimoto's disease
Thyroglobulin a Isaac's syndrome Voltage-gated potassium channels b
Insulin-dependent diabetes Glutamic acid decarboxylase (GAD) a
Insulin receptor a Insulin associated antigen (IA-w) a Heat shock
protein (Hsp) b Lambert-Eaton myasthenic Synaptogamin in
voltage-gated calcium syndrome (LEMS) channels b Multiple sclerosis
Myelin basic protein (MBP) a Proteolipid protein (PLP) a Myelin
oligodendrocyte-associated protein a (MOG) .alpha.B-crystallin a
Myasthenia Gravis Acetyl choline receptor (AchR) a Paraneoplastic
encephalitis RNA-binding protein HuD b Pemphigus vulgaris "PeV
antigen complex" a Desmoglein (DG) c Primary Biliary cirrhosis
Dihydrolipoamide acetyltransferase b Pyruvate dehydrogenase complex
2 (PDC- d E2) Progressive systemic DNA topoisomerase a sclerosis
RNA polymerase a Rheumatoid arthritis Immunoglobulin Fc a Collagen
Scleroderma Topoisomerase I b Stiff-man syndrome Glutamic acid
decarboxylase (GAD) a Systemic lupus erythematosus ds-DNA a Uveitis
Interphotoreceptor retinoid-binding protein b S antigen (rod out
segment) b References: a) HLA and Autoimmune Disease, R. Heard, pg.
123-151 in HLA & Disease, Academic Press, New York, 1994 (R.
Lechler, ed.) b) Steinman (1995) Cell 80: 7-10 c) Amagai et at.
(1991) Cell 67: 869-877 d) Shimoda et al. (1995) J. Exp. Med. 181:
1835-1845
[0096] TABLE-US-00005 TABLE 2 Class II Associated Peptides SEQ ID
Peptide Source Protein NO: GRTQDENPVVHFFKNIVTPRTPP MBP 80-102 8
AVYVYIYFNTWTTCQFIAFPFK PLP 170-191 9 TTNVRLKQQWVDYNLKW AChR .alpha.
32-67 10 QIVTTNVRLKQQWVDYNLKW AChR .alpha. 48-67 11 QWVDYNL AChR
.alpha. 59-65 12 GGVKKIHIPSEKIWRPDL AChR .alpha. 73-90 13
AIVKFTKVLLQY AChR .alpha. 101-112 14 WTPPAIFKSYCEIIVTHFPF AChR
.alpha. 118-137 15 MKLGTWTYDGSVV AChR .alpha. 144-156 16
MKLGIWTYDGSVV AChR .alpha. 144-157 17 analog (1-148) WTYDGSVVA AChR
.alpha. 149-157 18 SCCPDTPYLDITYHFVM AChR .alpha. 191-207 19
DTPYLDITYHFVMQRLPL AChR .alpha. 195-212 20 FIVNVIIPCLLFSFLTGLVFY
AChR .alpha. 214-234 21 LLVIVELIPSTSS AChR .alpha. 257-269 22
STHVMPNWVRKVFIDTIPN AChR .alpha. 304-322 23 NWVRKVFIDTIPNIMFFS AChR
.alpha. 310-327 24 IPNIMFFSTMKRPSREKQ AChR .alpha. 320-337 25
AAAEWKYVAMVMDHIL AChR .alpha. 395-410 26 IIGTLAVFAGRLIELNQQG AChR
.alpha. 419-437 27 GQTIEWIFIDPEAFTENGEW AChR .gamma. 165-184 28
MAHYNRVPALPFPGDPRPYL AChR .gamma. 476-495 29 LNSKIAFKIVSQEPA
desmoglein 3 190-204 30 TPMFLLSRNTGEVRT desmoglein 3 206-220 31
SQRHGSKYLATASTMDHARHG MBP 7-27 32 RDTGILDSIGRFFGGDRGAP MBP 33-52 33
QKSHGRTQDENPVVHFFKNI MBP 74-93 34 DENPVVHFFKNIVT MBP 84-97 35
ENPVVHFFKNIVTPR MBP 85-99 36 HFFKNIVTPRTPP MBP 90-102 37
KGFKGVDAQGTLSK MBP 139-152 38 VDAQGTLSKIIFKLGGRDSRS MBP 144-163
39
Nucleic Acids
[0097] The fusion polypeptides of the invention can be produced by
recombinant DNA technology. Nucleic acids of the invention encode
either a single .alpha.-MSH containing peptide (e.g., SYSMEHFRWGKPV
(SEQ ID NO:1), SYSMEHFRWGKPVG (SEQ ID NO:62), SYSMEHFRWGKPVGKK (SEQ
ID NO:63), SYSMEHFRWGKPVGKKR (SEQ ID NO:64), or SYSMEHFRWGKPVRSKR
(SEQ ID NO:69)) or an .alpha.-MSH containing peptide fused to
additional amino acid sequences, such as an additional .alpha.-MSH
containing peptide or peptides or any other sequences as described
herein.
[0098] The nucleic acids may be cloned into an expression vector,
i.e., a vector in which the coding sequence is operably linked to
expression control sequences. The need for, and identity of,
expression control sequences will vary according to the type of
cell in which the DNA is to be expressed. Generally, expression
control sequences include a transcriptional promoter, enhancer,
suitable mRNA ribosomal binding sites, translation start site, and
sequences that terminate transcription and translation, including
polyadenylation and possibly translational control sequences.
Suitable expression control sequences can be selected by one of
ordinary skill in the art. The nucleic acids encoding the
polypeptides described herein can encode a methionine residue at
the amino terminus of the polypeptide. Standard methods can be used
by the skilled person to construct expression vectors. See
generally, Sambrook et al., 1989, Molecular Cloning: A Laboratory
Manual (2nd Edition), Cold Spring Harbor Press, N.Y. Vectors useful
in this invention include linear nucleic acid fragments or circular
DNAs, plasmid vectors, viral vectors, fungal vectors, and bacterial
vectors. A "plasmid" is an autonomous, self-replicating,
extrachromosomal, circular DNA. Preferred viral vectors are those
derived from retroviruses, adenovirus, adeno-associated virus, pox
viruses, SV40 virus, alpha viruses or herpes viruses.
[0099] An example of an expression vector useful in the invention
is one in which a transcription sequence comprises: (a) a promoter
sequence, operably linked to; (b) a sequence encoding the first 52
amino acids (MPRSCCSRSGALLLALLLQASMEVRGWCLESSQCQDLTTESNLLECIRACKP;
SEQ ID NO:40) of the human POMC molecule, comprising a signal
sequence encoded by amino acids 1-26 and sorting signal encoded by
amino acids 27-52 of POMC; (c) a sequence encoding a joining
peptide of POMC or portion of a joining peptide which encodes the
natural protease cleavage site (KR) for .alpha.-MSH cleavage; (d)
an .alpha.-MSH containing peptide; and (e) a stop codon. Examples
of fusion polypeptides encoded by such a vector include:
TABLE-US-00006 MPRSCCSRSGALLLALLLQASMEVRGWCLESSQCQD (SEQ ID NO:42)
LTTESNLLECIRACKPREGKRSYSMEHFRWGKPV;
MPRSCCSRSGALLLALLLQASMEVRGWCLESSQCQD (SEQ ID NO:47)
LTTESNLLECIRACKPREGKRSYSMEHFRWGKPVG;
MPRSCCSRSGALLLALLLQASMEVRGWCLESSQCQD (SEQ ID NO:49)
LTTESNLLECIRACKPREGKRSYSMEHFRWGKPVGK K;
MPRSCCSRSGALLLALLLQASMEVRGWCLESSQCQD (SEQ ID NO:51)
LTTESNLLECIRACKPREGKRSYSMEHFRWGKPVGK KR; and
MPRSCCSRSGALLLALLLQASMEVRGWCLESSQCQD (SEQ ID NO:78)
LTTESNLLECIRACKPREGKRSYSMEHFRWGKPVRS KR.
[0100] Additionally, an .alpha.-MSH expression vector can contain
IRES (internal ribosome entry sites) sequences located between
nucleic acids encoding polypeptides described herein. For example,
a vector can contain IRES sequences between repeats of the
transcription sequence described in the paragraph above or between
a sequence encoding an .alpha.-MSH containing peptide and a
sequence encoding a therapeutic polypeptide. For a description of
IRES sequences and their use, see e.g., U.S. Pat. No.
6,087,129.
[0101] A nucleic acid can encode two separate polypeptides. The
first translational product of the nucleic acid can be any of the
.alpha.-MSH containing polypeptides described herein. The second
translational product of the nucleic acid can be, e.g., a
therapeutic polypeptide, a polypeptide that promotes the processing
of an .alpha.-MSH containing polypeptide, e.g., prohormone
convertase 1 (PC1; Li et al. (1999) Mol. Cell. Endocrinol.
158:143), or a selection marker, e.g., a drug resistance gene or a
fluorescent protein.
[0102] In one example, a nucleic acid vector has two promoters,
e.g., one promoter that drives expression of a sequence encoding an
.alpha.-MSH containing polypeptide, e.g., SEQ ID NO:42, and one
promoter that drives expression of a second polypeptide, e.g., PCd.
In another example, a nucleic acid contains IRES sequences located
between two coding sequences, e.g., between nucleic acid sequences
encoding the polypeptide of SEQ ID NO:42 and PC1. The IRES
sequences cause the ribosome to attach to the initiator codon of
the downstream translational unit and translate a second protein
from a single polycistronic mRNA.
[0103] In another example, a composition can include a first and a
second nucleic acid, wherein the first nucleic acid encodes an
.alpha.-MSH containing peptide and the second nucleic acid encodes
a second polypeptide, e.g., a therapeutic polypeptide. These
nucleic acids can be administered to an individual simultaneously
or at different times and can be contained in the same or different
delivery vehicles.
[0104] Nucleic acids can be used for the in vitro production of the
polypeptides of the invention. For example, a cell or cell line can
be transfected, transformed, or infected with a nucleic acid, e.g.,
an expression vector, described herein. After an incubation period
that permits expression of a polypeptide encoded by the nucleic
acid, the polypeptide can be purified from the cell culture media,
if secreted, or from a lysate of the cells expressing the
polypeptide.
Conjugates
[0105] The fusion polypeptides of the invention can be created by a
chemical coupling of a polypeptide including .alpha.-MSH to another
compound, e.g., a therapeutic compound, to form a conjugate. A
"conjugate" is a non-naturally occurring substance comprising an
.alpha.-MSH containing polypeptide that has been linked, covalently
or noncovalently, to a heterologous compound via the action of a
coupling agent. The link between two components may be direct,
e.g., where an .alpha.-MSH containing peptide is linked directly to
a heterologous compound, or indirect, e.g., where an .alpha.-MSH
containing peptide is linked to an intermediate, e.g., a backbone,
and that intermediate is also linked to the heterologous compound.
A coupling agent should function under conditions of temperature,
pH, salt, solvent system, and other reactants that substantially
retain the chemical stability of the .alpha.-MSH containing
peptide, the backbone (if present), and the heterologous
compound.
[0106] A coupling agent can link components without the inclusion
of the coupling agent in the resulting fusion polypeptide. Other
coupling agents do result in the inclusion of the coupling agent in
the resulting fusion polypeptide. For example, coupling agents can
be cross-linking agents that are homo- or hetero-bifunctional, and
wherein one or more atomic components of the agent are retained in
the composition. A coupling agent that is not a cross-linking agent
can be removed entirely following the coupling reaction, so that
the molecular product is composed entirely of the
.alpha.-MSH-containing polypeptide, the heterologous compound, and
a backbone moiety (if present).
[0107] Many coupling agents react with an amine and a carboxylate
to form an amide, or with an alcohol and a carboxylate to form an
ester. Coupling agents are known in the art, see, e.g., Greene and
Wuts (1991) "Protective Groups in Organic Synthesis," 2nd Ed., John
Wiley, NY. Coupling agents should link component moieties stably,
but such that there is minimal or no denaturation or deactivation
of the .alpha.-MSH containing polypeptide or the heterologous
compound.
[0108] The conjugates of the invention can be prepared by coupling
an .alpha.-MSH containing polypeptide to a heterologous compound
using methods known in the art. A variety of coupling agents,
including cross-linking agents, can be used for covalent
conjugation. Examples of cross-linking agents include
N,N'-dicyclohexylcarbodiimide (DCC; Pierce),
N-succinimidyl-S-acetyl-thioacetate (SATA),
N-succinimidyl-3-(2-pyridyldithio)propionate (SPDP),
ortho-phenylenedimaleimide (o-PDM), and sulfosuccinimidyl
4-(N-maleimidomethyl) cyclohexane-1-carboxylate (sulfo-SMCC). See,
e.g., Karpovsky et al. (1984) J. Exp. Med. 160:1686 and Liu et al.
(1985) Proc. Natl. Acad. Sci. USA 82:8648. Other methods include
those described by Paulus (1985) Behring Ins. Mitt. 78:118-132;
Brennan et al. (1985) Science 229:81-83; and Glennie et al. (1987)
J. Immunol. 139: 2367-2375. A large number of coupling agents for
peptides and proteins, along with buffers, solvents, and methods of
use, are described in the Pierce Chemical Co. catalog, pages
T-155-T-200, 1994 (3747 N. Meridian Rd., Rockford Ill., 61105,
U.S.A.; Pierce Europe B.V., P.O. Box 1512, 3260 BA Oud Beijerland,
The Netherlands), which catalog is hereby incorporated by
reference.
[0109] DCC is a useful coupling agent (Pierce #20320; Rockford,
Ill.). It promotes coupling of the alcohol NHS in DMSO (Pierce
#20684), forming an activated ester which can be cross-linked to
polylysine. DCC (N,N'-dicyclohexylcarbodiimide) is a
carboxy-reactive cross-linker commonly used as a coupling agent in
peptide synthesis, and has a molecular weight of 206.32. Another
useful cross-linking agent is SPDP (Pierce #21557), a
heterobifunctional cross-linker for use with primary amines and
sulfhydryl groups. SPDP has a molecular weight of 312.4 and a
spacer arm length of 6.8 angstroms, is reactive to NHS-esters and
pyridyldithio groups, and produces cleavable cross-linking such
that upon further reaction, the agent is eliminated so the
.alpha.-MSH containing polypeptide can be linked directly to a
backbone or heterologous compound. Other useful conjugating agents
are SATA (Pierce #26102) for introduction of blocked SH groups for
two-step cross-linking, which are deblocked with hydroxylamine-HCl
(Pierce #26103), and sulfo-SMCC (Pierce #22322), reactive towards
amines and sulfhydryls. Other cross-linking and coupling agents are
also available from Pierce Chemical Co. (Rockford, Ill.).
Additional compounds and processes, particularly those involving a
Schiff base as an intermediate, for conjugation of proteins to
other proteins or to other compositions, for example to reporter
groups or to chelators for metal ion labeling of a protein, are
disclosed in EP 243,929 A2 (published Nov. 4, 1987).
.alpha.-MSH Analogs
[0110] Any biologically active analog of .alpha.-MSH can be used in
place of .alpha.-MSH in the compositions and methods described
herein. By "biologically active" is meant possessing the ability to
bind to a melanocortin receptor. Preferably, a biologically active
analog of .alpha.-MSH can bind to a melanocortin receptor with an
affinity, e.g., a mM, gM, or nM affinity, sufficient to induce a
biological response, e.g., melanin synthesis, in a cell expressing
a melanocortin receptor. Preferably, a biologically analog of
.alpha.-MSH possesses one or more of the biological activities
described herein for an .alpha.-MSH peptide. For example, a
biologically analog of .alpha.-MSH may bind to a melanocortin
receptor, e.g., MC1-R, with a binding affinity of at least 50% of
that possessed by the SYSMEHFRWGKPV (SEQ ID NO:1) peptide.
[0111] An .alpha.-MSH analog can be linked to an additional amino
acid sequence or a therapeutic compound, as described herein with
respect to an .alpha.-MSH peptide. An .alpha.-MSH analog consisting
of naturally occurring amino acids can be encoded by a nucleic acid
and can be optionally linked to other amino acid sequences in the
form of a fusion protein.
[0112] An .alpha.-MSH analog can have either the same or a
different receptor specificity as compared to a naturally occurring
.alpha.-MSH, e.g., the SYSMEHFRWGKPV (SEQ ID NO:1) peptide. For
example, an .alpha.-MSH analog may bind to or activate a single
specific melanocortin receptor subtype, e.g. MC1-R, or to a subset
of melanocortin receptor subtypes, e.g., MC1-R and MC5-R. An
.alpha.-MSH analog can be used that does not bind to specific
subtypes of melanocortin receptors, e.g., receptors expressed in
brain tissue such as MC3-R and/or MC4-R.
[0113] The amino acid residues at particular positions may include
analogs, derivatives and congeners of any specific amino acid
referred to herein. For example, the present invention contemplates
the use of amino acid analogs wherein a side chain is lengthened or
shortened while still providing a carboxyl, amino or other reactive
precursor functional group for cyclization, as well as amino acid
analogs having variant side chains with appropriate functional
groups. For instance, the subject peptide can include an amino acid
analog such as .beta.-cyanoalanine, canavanine, djenkolic acid,
norleucine, 3-phosphoserine, homoserine, dihydroxyphenylalanine,
5-hydroxytryptophan, 1-methylhistidine, or 3-methylhistidine. Other
naturally occurring amino acid metabolites or precursors having
side chains which are suitable herein will be recognized by those
skilled in the art and are included in the scope of the present
invention.
[0114] Analogs of .alpha.-MSH can be generated by mutagenesis, such
as by discrete point mutation(s), or by truncation. For instance,
mutation can give rise to analogs which retain substantially the
same, or merely a subset, of the biological activity of the
polypeptide from which it was derived.
[0115] The polypeptides that can be utilized in the present
invention also include analogs of .alpha.-MSH that are resistant to
proteolytic cleavage such as those that, due to mutations, alter
ubiquitination or other enzymatic targeting associated with the
protein.
[0116] Polypeptide analogs may also be chemically modified to
create derivatives by forming covalent or aggregate conjugates with
other chemical moieties, such as glycosyl groups, lipids,
phosphate, acetyl groups and the like. Covalent derivatives of
proteins can be prepared by linking the chemical moieties to
functional groups on amino acid sidechains of the protein or at the
N-terminus or at the C-terminus of the polypeptide.
[0117] Modification of the structure of the subject polypeptides
can be for such purposes as enhancing therapeutic or prophylactic
efficacy, stability (e.g., ex vivo shelf life and resistance to
proteolytic degradation in vivo), or post-translational
modifications (e.g., to alter the phosphorylation pattern of the
polypeptide). Such modified peptides, when designed to retain at
least one activity of a naturally-occurring form of .alpha.-MSH,
are considered functional equivalents of the polypeptides described
herein. Such modified peptides can be produced, for instance, by
amino acid substitution, deletion, or addition.
[0118] For example, it is reasonable to expect that an isolated
replacement of a leucine with an isoleucine or valine, an aspartate
with a glutamate, a threonine with a serine, or a similar
replacement of an amino acid with a structurally related amino acid
(i.e. isosteric and/or isoelectric mutations) will not have a major
effect on the biological activity of the resulting molecule.
Conservative replacements are those that take place within a family
of amino acids that are related in their side chains. Genetically
encoded amino acids are can be divided into four families: (1)
acidic=aspartate, glutamate; (2) basic=lysine, arginine, histidine;
(3) nonpolar=alanine, valine, leucine, isoleucine, proline,
phenylalanine, methionine, tryptophan; and (4) uncharged
polar=glycine, asparagine, glutamine, cysteine, serine, threonine,
tyrosine. In similar fashion, the amino acid repertoire can be
grouped as (1) acidic=aspartate, glutamate; (2) basic=lysine,
arginine histidine, (3) aliphatic=glycine, alanine, valine,
leucine, isoleucine, serine, threonine, with serine and threonine
optionally grouped separately as aliphatic-hydroxyl; (4)
aromatic=phenylalanine, tyrosine, tryptophan; (5) amide=asparagine,
glutamine; and (6) sulfur-containing=cysteine and methionine (see,
e.g., Biochemistry, 2nd ed., Ed. by L. Stryer, W H Freeman and Co.:
1981). Whether a change in the amino acid sequence of a peptide
results in a functional analog (e.g., functional in the sense that
the resulting peptide mimics a function of a peptide containing the
sequence of SYSMEHFRWGKPV (SEQ ID NO:1)) can be readily determined
by assessing the ability of the variant peptide to produce a
response in cells in a fashion similar to an .alpha.-MSH peptide.
Polypeptides in which more than one replacement has taken place can
readily be tested in the same manner.
[0119] As set forth above, alterations in primary sequence include
genetic variations, both natural and induced. Also included are
analogs that include residues other than naturally occurring
L-amino acids, e.g., D-amino acids or non-naturally occurring or
synthetic amino acids, e.g., .beta. or .delta. amino acids.
Alternatively, increased stability or solubility may be conferred
by cyclizing the peptide molecule.
[0120] Nonsequence modifications include in vivo or in vitro
chemical derivatization of polypeptides, e.g., acetylation,
methylation, phosphorylation, carboxylation, or glycosylation.
Glycosylation can be modified, e.g., by modifying the glycosylation
patterns of a polypeptide during its synthesis and processing or in
further processing steps, e.g., by exposing the polypeptide to
glycosylation-affecting enzymes derived from cells that normally
provide such processing, e.g., mammalian glycosylation enzymes.
Phosphorylation can be modified by exposing the polypeptide to
phosphorylation-altering enzymes, e.g., kinases or
phosphatases.
[0121] It will be appreciated by those of skill in the art that a
peptide mimic may serve equally well as a peptide for the purpose
of providing the specific backbone conformation required for
binding to melanocortin receptors and eliciting appropriate
biological responses, e.g., the generation of regulatory T cells.
Accordingly, it is contemplated as being within the scope of the
present invention to produce .alpha.-MSH analogs through the use of
naturally-occurring amino acids, amino acid derivatives, analogs or
non-amino acid molecules capable of being joined to form the
appropriate backbone conformation. A non-peptide analog, or an
analog comprising peptide and non-peptide components, is sometimes
referred to herein as a "peptidomimetic" or sometimes as an
"isosteric peptidomimetic" to designate substitutions or
derivations of peptide-based .alpha.-MSH analogs that possess the
same backbone conformational features and/or other
functionalities.
[0122] The use of isosteric peptidomimetics for the development of
high-affinity and/or selective peptide analogs is well known in the
art. Of particular relevance to the present invention, mimics of
peptide backbone structures, such as .alpha.-helicies, .beta.-turns
and .beta. sheets, have been developed. For example, Kemp et al.
(1988) Tetrahedron Lett. 29:5057 disclose derivatives of dilactams
of L-.alpha., .delta.-diaminobutyric acid and D-glutamic acid as a
constrained .beta.-turn template, particularly for the selective
stabilization of type II .beta.-turns. Kahn et al. (1988) J. Amer.
Chem. Soc. 110:1638 disclose a non-peptide mimetic of .beta.-turns
produced by oxidative intramolecular cycloaddition of an
azodicarbonyl system. As another example, Olson et al. (1990) J.
Amer. Chem. Soc. 112:323 disclose a model tetrapeptide mimetic of a
type II' .beta.-turn produced from a 9-membered ring lactam system.
Numerous other peptide mimetic structures useful for the practice
of the present invention are available and will be apparent to
those of skill in the art (see, e.g., Peptides: Chemistry,
Structure and Biology (1990), J. E. Rivier & G. R. Marshall,
eds., ESCOM Publishers, Leiden, Netherlands). Assuming rotational
constraints similar to those of amino acid residues within a
peptide, analogs comprising non-amino acid moieties may be
analyzed, and their conformational motifs verified, by means of the
Ramachandran plot.
[0123] Examples of .alpha.-MSH analogs that can be used in the
compositions and methods of the present invention are described in
U.S. Pat. No. 4,866,038, U.S. Pat. No. 5,830,994, U.S. Pat. No.
5,157,023, WO 96/41815, Brandenburger et al. (1999) J. Recept.
Signal. Transduct. Res. 19:467, Giblin et al. (1998) Proc. Natl.
Acad. Sci. USA 95:12814, and Hruby et al. (1995) J. Med. Chem.
38:3454. The content of each of these references is hereby
incorporated by reference.
Delivery Systems
[0124] The invention encompasses systems and methods for the in
vitro, in vivo, and ex vivo delivery of the nucleic acids,
polypeptides, and analogs of the invention. A variety of methods of
delivering the compositions described herein are well know to those
of skill in the art.
[0125] The polypeptides, analogs, or nucleic acids, can be
administered using standard methods, e.g., those described in
Donnelly et al. (1994) J. Imm. Methods 176:145, and Vitiello et al.
(1995) J. Clin. Invest. 95:341. Polypeptides, analogs, and nucleic
acids of the invention can be injected into subjects in any manner
known in the art,, e.g., intramuscularly, intravenously,
intraarterially, intradermally, intraperitoneally, intranasally,
intravaginally, intrarectally or subcutaneously, or they can be
introduced into the gastrointestinal tract, the mucosa, or the
respiratory tract, e.g., by inhalation of a solution or powder
containing the polypeptides or nucleic acids. Alternately, the
polypeptides, analogs, or nucleic acids of the invention may be
applied to the skin, or electroporated into the cells or tissue.
Alternately, the polypeptides, analogs, or nucleic acids of the
invention may be treated with ultrasound to cause entry into the
cells or tissue. Long lasting continuous release of the
polypeptides, analogs or nucleic acids of the invention can also be
obtained, for example, through the use of osmotic pumps.
[0126] The polypeptides, analogs, and nucleic acids encoding
polypeptides can be delivered in a pharmaceutically acceptable
carrier such as saline. The nucleic acid can be naked or associated
or complexed with a delivery vehicle. For a description of the use
of naked DNA, see e.g., U.S. Pat. No. 5,693,622. Nucleic acids and
polypeptides can be delivered using delivery vehicles known in the
art, such as lipids, depot systems, hydrogel networks,
particulates, liposomes, ISCOMS, microspheres or nanospheres,
microcapsules, microparticles, gold particles, virus-like
particles, nanoparticles, polymers, condensing agents,
polysaccharides, polyamino acids, dendrimers, saponins, adsorption
enhancing materials, colloidal suspensions, dispersions, powders,
or fatty acids.
[0127] Viral particles can also be used, e.g., retroviruses,
adenovirus, adeno-associated virus, pox viruses, SV40 virus, alpha
virus or herpes viruses.
[0128] It is expected that a dosage of approximately 0.1 to 100
.mu.moles of the polypeptide, or of about 1 to 200 .mu.g of DNA,
would be administered per kg of body weight per dose. As is well
known in the medical arts, dosage for any given patient depends
upon many factors, including the patient's size, body surface area,
age, the particular compound to be administered, sex, time and
route of administration, general health, and other drugs being
administered concurrently. Determination of optimal dosage is well
within the abilities of a pharmacologist of ordinary skill.
[0129] Other standard delivery methods, e.g., biolistic transfer,
or ex vivo treatment, can also be used. In ex vivo treatment,
cells, e.g., APCs, dendritic cells, peripheral blood mononuclear
cells, or bone marrow cells, can be obtained from a patient or an
appropriate donor and treated ex vivo with a composition of the
invention, and then returned to the patient.
[0130] Microparticles or nanoparticles, including those described
in U.S. Pat. No. 5,783,567 and U.S. Ser. No. 60/208,830, filed Jun.
2, 2000, can be used as vehicles for delivering macromolecules such
as DNA, RNA, or polypeptides into cells. The microparticles can
contain macromolecules embedded in a polymeric matrix or enclosed
in a shell of polymer. Microparticles act to maintain the integrity
of the macromolecule, e.g., by maintaining the DNA in a nondegraded
state. Microparticles can also be used for pulsed delivery of the
macromolecule, and for delivery at a specific site or to a specific
cell or target cell population.
[0131] The polymeric matrix can be a synthetic or natural
biodegradable co-polymer such as poly-lactic-co-glycolic acid,
starch, gelatin, or chitin. Microparticles that are less than 10
.mu.M in diameter can be used in particular to maximize delivery of
DNA molecules into a subject's phagocytotic cells. Alternatively,
microparticles that are greater than 10 .mu.M in diameter can be
injected or implanted in a tissue, where they form a deposit. As
the deposit breaks down, the nucleic acid or polypeptide is
released gradually over time and taken up by neighboring cells.
[0132] The microparticles can be delivered directly into an
individual's bloodstream (e.g., by intravenous or intraarterial
injection or infusion) preferably if uptake by the phagocytic
cells, e.g., phagocytic cells of the reticuloendothelial system
(RES), is desired. Additionally, microparticles can be targeted,
via subcutaneous injection, for uptake by the phagocytic cells of
the draining lymph nodes. The microparticles can also be introduced
intradermally, e.g., to the APCs of the skin, such as dendritic
cells and Langerhans cells. Another useful route of delivery,
particularly for DNAs encoding tolerance-inducing polypeptides, is
via the gastrointestinal tract, e.g., orally. Additionally,
microparticles can be introduced into the lung, e.g., by inhalation
of powdered microparticles or of a nebulized or aerosolized
solution containing the microparticles, where the particles can be
taken up by alveolar macrophages. Once a phagocytic cell
phagocytoses a microparticle, the nucleic acid is released into the
interior of the cell. Upon release, the nucleic acid expresses the
encoded polypeptide, using the cellular transcription and
translation machinery.
[0133] The polypeptides, analogs, and nucleic acids of the
invention can be administered into subjects via lipids, dendrimers,
microspheres, colloids, suspensions, emulsions, depot systems,
hydrogel networks, liposomes, or electroporation using techniques
that are well known in the art. For example, liposomes carrying
polypeptides or nucleic acids encoding polypeptides can be
delivered as described in Reddy et al. (1992) J. Imrunol. 148:1585;
Collins et al. (1992) J. Immunol. 148:3336-3341; Fries et al.
(1992) Proc. Natl. Acad. Sci. USA 89:358; and Nabel et al. (1992)
Proc. Nat. Acad. Sci. USA 89:5157. Examples of hydrogel networks
are described in U.S. Ser. No. 60/270,256, filed Feb. 20, 2001.
[0134] The peptides, analogs, and nucleic acids of the invention
can be administered by using ISCOMS, which are negatively charged,
cage-like structures of 30-40nm in size formed spontaneously on
mixing cholesterol and Quil A (saponin), or saponin alone. A
peptide (or analog) and nucleic acid of the invention can be
co-administered with an ISCOM, or the peptide (or analog) and
nucleic acid can be administered separately. The peptides, analogs,
and nucleic acids of the invention may also be electroporated into
cells or tissues of a recipient. Electroporation may occur ex vivo
or in vivo.
Methods of Use
[0135] The nucleic acid compositions of the invention can be used
to produce recombinant .alpha.-MSH containing peptides in cells.
For example, an expression vector encoding an
.alpha.-MSH-containing polypeptide can be transfected into a cell,
e.g., bacteria or mammalian cells such as yeast cells, and an
.alpha.-MSH containing peptide can be purified from the culture
medium. The compositions of the invention may be used to produce
.alpha.-MSH containing peptides in cells that either normally
express or do not express .alpha.-MSH. Expression may be controlled
via a specific promoter or regulatory sequence in the nucleic acid
or recombinant .alpha.-MSH protein. Expression of the recombinant
.alpha.-MSH containing peptide may induce expression of the
cellular .alpha.-MSH by the transfected cell or other cells.
[0136] As described in the Examples, the transfection of a cell
with a nucleic acid encoding an .alpha.-MSH containing peptide
induces melanin synthesis in the transfected cell and/or in another
cell exposed to the supernatant of a transfected cell. Melanin
synthesis is associated with increased cellular pigmentation, a
phenomenon which can be readily detected by using assays such as
those described in the Examples. Because the nucleic acids
described herein produce a polypeptide that induces a readily
detectable color change in a transfected cell (or in a cell exposed
to the supernatant of a transfected cell), the nucleic acids can be
used in a variety of reporter assays. In one example, a nucleic
acid construct encoding an .alpha.-MSH containing peptide can be
used to evaluate promoter activity. In such a method, a promoter
sequence or a candidate promoter sequence is operatively linked to
the nucleic acid construct, and the induction of melanin synthesis
following transfection of a cell with the construct is evaluated.
According to this method, a change in coloration following
transfection is indicative of promoter activity. This method can
optionally include evaluating the ability of a test compound to
modulate (increase or decrease) expression regulated by the
promoter or candidate promoter sequence. In a similar fashion, a
nucleic acid construct encoding an .alpha.-MSH containing peptide
can be used as a reporter to evaluate an expression vector for its
ability to produce a gene product. In a second example, a nucleic
acid construct encoding an .alpha.-MSH containing peptide can be
used to evaluate the efficiency of gene transfer methods. In one
method, a transfection protocol can be optimized by transfecting
cells under a variety of conditions with a nucleic acid described
herein, wherein the efficiency of the gene transfer under each of
the conditions is determined by measuring melanin synthesis.
[0137] The compositions of the invention can also be used to effect
a wide variety of immunomodulatory functions, e.g.,
anti-inflammatory functions, in vitro and in vivo. For example, the
.alpha.-MSH compositions can be used to inhibit the activity of
various cells and/or molecules of the immune system. In some cases,
the .alpha.-MSH compositions can inhibit one or more of the
following: histamine release from mast cells; neutrophil chemotaxis
and/or migration to an inflamed site; macrophage activation; the
expression of costimulatory factors, e.g., CD86 and/or CD40, by
APCs; or the secretion of cytokines such as IL-12, IFN-.lamda. and
TNF-.alpha.. In some cases, the o-MSH compositions can promote
secretion of TGF.beta. and/or IL-10.
[0138] The compositions of the invention, e.g., nucleic acids,
polypeptide, conjugates, and analogs, can also be used to induce
tolerance and/or to induce a regulatory T cell response, either in
vitro or in vivo. For example, a regulatory T cell response can be
induced by administration of an .alpha.-MSH-containing polypeptide
or by co-administration of an .alpha.-MSH-containing polypeptide
and a therapeutic polypeptide.
[0139] An .alpha.-MSH composition can also be used to alter the
activity of macrophages, monocytes, dendritic cells, or other
phagocytic cells. In addition, an .alpha.-MSH composition can be
used to elicit anti-inflammatory activities in vitro or in vivo.
Examples of anti-inflammatory activities include: (1) inhibition of
hepatic nitric oxide and leukocyte infiltration in mice pretreated
with Corynebacterium parvum followed by an acute injection of
lipopolysaccharide; (2) inhibition of the development of chronic
inflammation in mycobacterium-induced rats; (3) inhibition of the
colonic and intestinal tract inflammation that ensues in mice
following intra-rectal treatment with TNBS in ethanol; (4)
improvements of aspects of systemic inflammatory-response syndrome;
(5) decreased histamine release by mast cells; (6) decreased
neutrophil migration; (7) decreased macrophage activation as
demonstrated by reduction of IL-12, IFN-.gamma. or TNF.alpha.
production and/or a change in cell surface markers; (8) decreased
dendritic cell activation measured by altered cytokine production
or changes in cell surface expressed activation marker; (9)
decrease in the number and/or size of plaques in the brain of
mammals with Alzheimer's or a related disease; and (10) decreased
production of immunoglobulin. The compositions of the invention,
e.g., nucleic acids, polypeptide, conjugates, and analogs, can be
used to stimulate cellular production of various molecules, e.g.
IL-10, TGF-.beta., endogenous .alpha.-MSH, or melanin (for example
by melanocytes). Alternatively, the compositions can be used to
reduce cellular production of various molecules, e.g., IL-1,
TNF-.alpha., IFN-.gamma., IL-12, and/or endogenous .alpha.-MSH.
Furthermore, because an .alpha.-MSH composition can reduce
NF-.kappa.B activation by a cell, the compositions can be useful
for treating conditions associated with NF-.kappa.B activation,
such as inflammatory disorders, cell proliferation and cancer.
[0140] Nucleic acids, polypeptides, and/or analogs of the invention
can be used to treat disorders such as inflammatory disorders,
autoimmunity, or neurological disorders, e.g., neuro-inflammatory
disorders. Examples of disorders that can be treated include
rheumatoid arthritis, asthma, rhinitis, sepsis, interstitial
cystitis, cystitis, Alzheimer's disease, symptoms associated with
chronic dialysis, erectile dysfunction, obesity, experimental
autoimmune encephalitis, cirrhosis, dermatitis, psoriasis, contact
hypersensitivity, inflammatory bowel disease, spinal cord injury,
diabetes, multiple sclerosis, lupus, uveitis, and coleiac disease.
These disorders can be treated by delivering to an individual a
nucleic acid, a polypeptide, an analog, or a combination thereof,
e.g., a nucleic acid encoding .alpha.-MSH and a therapeutic
polypeptide, or a nucleic acid encoding an .alpha.-MSH analog and a
nucleic acid encoding a therapeutic polypeptide.
[0141] A nucleic acid encoding an .alpha.-MSH polypeptide of the
invention can be used to treat an inflammatory disorder. The
delivery of a nucleic acid to a target cell and the expression of
.alpha.-MSH therein can result in an inhibition of the secretion of
interferon (IFN)-gamma by T cells (e.g., autoreactive T cells) and
decrease the effects of other mediators of inflammation as well.
This inhibition of immune activity is expected to ameliorate the
inflammatory condition.
[0142] Compositions described herein can be used to generate
regulatory T cells, either in vitro or in vivo. For example, a
population of T cells can be contacted in vitro with a therapeutic
compound, e.g., an autoantigen, and an .alpha.-MSH polypeptide or
an .alpha.-MSH analog. Regulatory T cells generated in vitro by
this method can then be introduced into a subject. The regulatory T
cells generated and administered in this method can be either
autologous, allogeneic, or xenogeneic. The regulatory T cells can
be used to ameliorate one or more symptoms of a condition such as
autoimmunity or inflammation when introduced into the subject.
[0143] In addition to the in vitro stimulation methods, a
therapeutic compound and an cc-MSH polypeptide or an .alpha.-MSH
analog can be delivered directly to an individual. The compositions
can optionally be delivered via a delivery vehicle as described
herein. This in vivo delivery method can be used to generate
regulatory T cells, or to reduce the symptoms of autoimmunity or
inflammation.
[0144] In one example, rheumatoid arthritis is treated by delivery
of an .alpha.-MSH containing peptide to an arthritic joint, e.g.,
by injection of a nucleic acid such as a recombinant adenovirus
encoding .alpha.-MSH. The recombinant adenovirus infects cells in
the joint, resulting in expression and secretion of the .alpha.-MSH
containing peptide by the infected cells. The local production of
an .alpha.-MSH containing peptide is expected to result in a
decreased production of inflammatory mediators and a decreased
production of IL-1 and TNF-.alpha. by immune cells that are present
in or migrate to the inflamed joint.
[0145] In another example, asthma is treated by, for example,
aerosolizing liposomes (or powdered liposomes) containing plasmid
DNA encoding an .alpha.-MSH containing peptide and delivering the
aerosol to the lung by methods known in the art. Cells of the lung,
e.g., epithelial cells, take up the liposomes, express the
.alpha.-MSH containing peptide, and result in suppression of the
inflammation associated with asthma, e.g., by decreasing
neutrophilia and production of TNF-.alpha. and NO. In this example,
long term (e.g., months) production of .alpha.-MSH is not required.
The delivery of a plasmid encoding the peptide provides for
localized, short term (e.g., days or weeks) activity of the peptide
and thus would be more potent than a single dose delivery of the
peptide alone.
[0146] In another example, cirrhosis is treated, for example, by
injecting microspheres containing DNA encoding an .alpha.-MSH
containing peptide into an individual by a route that favors
delivery of the particles to the liver, e.g., intravenous or
intra-hepatic artery injection. Localized production of the
.alpha.-MSH containing peptide by cells, e.g., hepatocytes or
Kupfer cells, is expected to reduce inflammation and result in an
improvement of cirrhosis.
[0147] In another example, a skin disorder is treated, for example,
by targeting a plasmid encoding an .alpha.-MSH containing peptide
to the skin by complexation of the plasmid with gold particles and
delivery through a gene gun. For a description of gene transfer
using a gene gun, see, e.g., U.S. Pat. No. 5,865,796. Expression of
an .alpha.-MSH containing peptide by keratinocytes and Langerhans
cells is expected to result in improvement of conditions such as
dermatitis, psoriasis, and/or contact hypersensitivity.
[0148] In another aspect, a nucleic acid encoding an .alpha.-MSH
containing peptide and an autoantigen can be used to treat an
inflammatory disorder or an autoimmune disease. In this method, DNA
encoding an .alpha.-MSH containing peptide and the autoantigen are
delivered to and expressed in a target organ or tissue. This
delivery and expression may occur at a disease site (e.g., an
arthritic joint, colon, brain) or in the periphery (e.g., muscle,
GALT, skin, lymph node, or spleen). .alpha.-MSH prevents
TNF-.alpha. and IL-1 production and causes APCs to produce IL-10
(and possibly others) (Luger et aL. (1997) J Investig Dermatol Symp
Proc 2:87). Because IL-10 production by APCs can induce regulatory
T cells that decrease the severity of autoimmune disease (Constant
et al. (1997) Ann Rev Immunol 15:297), the production of an
.alpha.-MSH containing peptide and an autoantigen in the periphery
should generate regulatory T cells specific for the expressed
autoantigen. The induced regulatory T cells are expected to home to
the site of antigen expression in the periphery (e.g., the pancreas
for diabetes) and to modulate the activity of the disease-inducing
T cell population so as to prevent or improve the disease
symptoms.
[0149] In another aspect, an .alpha.-MSH-containing polypeptide (or
a nucleic acid encoding an .alpha.-MSH-containing polypeptide) can
be administered to an individual together with a therapeutic
compound (or a nucleic acid encoding a therapeutic compound), as
the term is used herein. The .alpha.-MSH-containing polypeptide and
therapeutic compound can either be physically associated, e.g.,
fused or conjugated, or contained within the same vessel but not
physically associated. Alternatively, the .alpha.-MSH-containing
polypeptide and the therapeutic compound can be contained within
separate containers.
[0150] An example of a therapeutic compound that can be
administered according to this method is an interferon beta (e.g.,
interferon beta-1 such as interferon beta-1a or interferon
beta-1b)-containing composition. Interferon beta-containing
compositions can cause adverse skin reactions when administered to
an individual having multiple sclerosis (see, e.g., Walther et al.
(1999) Neurology 53:1622-27). Although interferon beta-containing
compositions can be beneficial in reducing the symptoms of multiple
sclerosis or slowing disease progression, the side effects of their
administration can be undesirable. By co-administration of an
.alpha.-MSH-composition together with an interferon beta-containing
composition, the .alpha.-MSH-composition can reduce or eliminate
one or more of the adverse immunologic reactions associated with
interferon beta administration.
[0151] In one example, multiple sclerosis is treated, for example,
by feeding to a mammal microspheres containing DNA encoding an
.alpha.-MSH containing peptide and MBP. APCs phagocytose the
microspheres and express the .alpha.-MSH containing peptide and MBP
peptides. The MBP is processed and presented by the APC to activate
T cells. The APC also produces .alpha.-MSH that causes the APC
and/or surrounding APCs to secrete IL-10. In the presence of IL-10,
the MBP-specific T cells become regulatory T cells, which then
target disease sites. Once at the disease site (e.g., the brain or
central nervous system) the regulatory T cells downregulate the
activity of the disease-inducing T cells.
[0152] In another example, diabetes is treated using a
liposome/plasmid complex to deliver DNA to the spleen or lymph
nodes of an individual. In this example, the plasmid (or plasmids)
encode an .alpha.-MSH containing peptide and insulin.
[0153] In another example, autoimmune encephalitis is treated or
prevented by delivering nucleic acids or microparticles containing
nucleic acids of the invention to a mammal. Plasmid DNA constructs
that express an .alpha.-MSH containing peptide may reduce the
occurrence and severity of the disease.
[0154] In another example, coeliac disease is treated, for example,
by feeding to a mammal microspheres containing plasmid DNA encoding
an .alpha.-MSH containing peptide and glutenin.
[0155] In another example, rheumatoid arthritis is treated, for
example, by targeting a plasmid encoding an .alpha.-MSH containing
peptide and collagen to the skin by complexation with gold
particles and delivery through a gene gun.
[0156] In another example, an allergic condition is treated by
targeting a plasmid encoding an .alpha.-MSH containing peptide and
a therapeutic polypeptide to the site of an allergic reaction.
[0157] In another example, a composition of the invention is
delivered to an individual to reduce fever in the individual.
[0158] In another example, a composition of the invention is
delivered to an individual to induce melanin production in the
individual.
[0159] In another example, the compositions of the invention are
used to reduce obesity, reduce weight gain and/or cause weight
reduction in a subject, e.g., a POMC or leptin deficient mammal.
POMC deficient mice and humans have an obese phenotype (see, e.g.,
Krude et al. (1998) Nat. Genet. 19:155-157 and Yaswen et al. (1999)
Nat. Med. 5:1066-1070, herein incorporated by reference). Treatment
of POMC deficient mice with an .alpha.-MSH peptide analog has been
found to lead to weight reduction. However, the treatment required
daily injections into the peritoneal cavity of a large amount of
peptide analog (Yaswen et al. supra). Providing a subject with a
nucleic acid encoding an .alpha.-MSH containing peptide described
herein would elicit a beneficial effect with fewer administrations
and reduce the need for daily treatments of the subject, e.g.,
permitting weekly, monthly or yearly treatments.
[0160] The following are examples of the practice of the invention.
They are not to be construed as limiting the scope of the invention
in any way.
EXAMPLES
Example 1
Construction of Expression Vectors
[0161] The structure of the POMC polypeptide is depicted in FIG.
1A. The location of various regions and features of POMC are
indicated by reference to specific amino acid residues indicated
below the depiction of the polypeptide. A polypeptide consisting of
POMC amino acid sequences 1-26, 27-52, 138-150, and a linker
sequence is depicted in FIG. 1B. This polypeptide has been
designated miniPOMC. The construction and activity of nucleic acids
encoding miniPOMC, as well as nucleic acids encoding other fusion
polypeptides, is described in this and the following examples.
[0162] Oligonucleotides encoding the human POMC signal peptide, the
human POMC sorting peptide, a partial junction peptide, and the
sequence SYSMEHFRWGKPV (SEQ ID NO:1) were synthesized in vitro. The
POMC oligonucleotides were constructed based upon the human POMC
cDNA sequence (GenBank.TM. Accession NM.sub.--000939). The
synthesized oligonucleotides were annealed and subdloned into
HindIII and Xhol sites of pCMV-Script (Stratagene, San Diego) to
generate the plasmid pCMV-miniPOMC. The following restriction
enzyme sites were incorporated into the cDNA construct via
oligonucleotide synthesis: HindIII and BssHII sites were placed
upstream of the start codon; and BamHI and Xhol sites were placed
downstream of the stop codon. Both the nucleotide (SEQ ID NO:43)
and amino acid (SEQ ID NO:42) sequences of the miniPOMC construct
are depicted in FIG. 2A.
[0163] Four additional oligonucleotides were synthesized encoding
polypeptides containing the fusion polypeptide sequence of FIG. 2A,
plus an additional one, three, or four amino acids at the carboxy
end of the polypeptide. These constructs were designated
ACTH(1-14), ACTH(1-16), ACTH(1-17), and .alpha.-MSH-f. FIG. 2B
depicts the nucleotide (SEQ ID NO:46) and amino acid (SEQ ID NO:47)
sequences of ACTH(1-14). FIG. 2C depicts the nucleotide (SEQ ID
NO:48) and amino acid (SEQ ID NO:49) sequences of ACTH (1-16). FIG.
2D depicts the nucleotide (SEQ ID NO:50) and amino acid (SEQ ID
NO:51) sequences of ACTH(1-17). FIG. 2E depicts the nucleotide (SEQ
ID NO:79) and amino acid (SEQ ID NO:78) sequences of .alpha.-MSH-f.
As compared to the miniPOMC polypeptide of FIG. 2A, ACTH(1-14)
contains an additional G at its carboxy terminus, ACTH(1-16)
contains an additional GKK at its carboxy terminus, ACTH(1-17)
contains an additional GKKR (SEQ ID NO:45) at its carboxy terminus,
and .alpha.-MSH-f contains an additional RSKR (SEQ ID NO:80) at its
carboxy terminus. The sequence of GKK comprises and amidation
signal. The nucleic acid constructs were subcloned in to the vector
pCMV-Script, as described above.
[0164] The miniPOMC construct (FIG. 2A) was excised from
pCMV-miniPOMC, by a BssHII and BamHI digest, and subcloned into the
BssHII and BamHI sites of the expression vector pZYC to generate
pZYC-miniPOMC (FIG. 3). pZYC is a modification of the pBIOTOPE
plasmid described in U.S. Pat. No. 6,013,258.
[0165] Two copies of the miniPOMC construct (FIG. 2A) were
subcloned into the vector pIRES (Clontech, CA) at multiple cloning
sites A and B to generate the vector pIRES-2X miniPOMC. The
pIRES-2X miniPOMC expression vector was generated as follows. pIRES
was digested with NheI and the ends were blunted using the large
(Klenow) fragment of DNA Polymerase I (BioLabs, MA). The resulting
vector was further digested with XhoI. A miniPOMC fragment was
excised from pCMV-miniPOMC by EcoRV (blunt) and Xhol digests. This
fragment was then cloned into the blunt-XhoI pIRES vector to
generate pIRES-miniPOMC. pIRES-miniPOMC was then digested with
NotI, treated with Klenow to create a blunt end, and then further
digested with XmaI. A miniPOMC fragment was removed from
pCMV-miniPOMC, digested with XhoI, blunted with Klenow, and then
further digested with XmaI. The XhoI-XmaI miniPOMC fragment was
then cloned into the blunt-XmaI pIRES-miniPOMC vector to generate
pIRES-2X miniPOMC.
Example 2
Construction of .alpha.-MSH/Serum Albumin Fusion Polypeptides
[0166] Three .alpha.-MSH/serum albumin fusion polypeptides are
depicted in FIG. 4. The polypeptides contain: (a) mouse serum
albumin signal peptide (MKWVTFLLLLFVSGSAFS; SEQ ID NO:52) or human
serum albumin signal peptide (MKWVTFISLLFLFSSAYS; SEQ ID NO:53);
(b) mouse or human serum albumin propeptide (RGVFRR; SEQ ID NO:54);
(c) the first 195 amino acids of mouse serum albumin
(EAHKSEIAHRYNDLGEQHFKGLVLIAFSQYLQKCSYDEHAKLVQEVTD
FAKTCVADESAANCDKSLHTLFGDKLCAIPNLRENYGELADCCTKQEPERNECF
LQHKDDNPSLPPFERPEAEAMCTSFKENPTTFMGHYLHEVARRHPYFYAPELLY
YAEQYNEILTQCCAEADKESCLTPKLDGVKEKALVSSVR; SEQ ID NO:55) or human
serum albumin (DAHKSEVAHRFKDLGEENFKALVLIAFAQYLQQCPFEDH
VKLVNEVTEFAKTCVADESAENCDKSLHTLFGDKLCTVATLRETYGEMADCCA
KQEPERNECFLQHKDDNPNLPRLVRPEVDVMCTAFHDNEETFLKKYLYEIARRH
PYFYAPELLFFAKRYKAAFTECCQAADKAACLLPKLDELRDEGKASSAK; SEQ ID NO:56);
(d) a linker (GGYGG; SEQ ID NO:57); (e) a furin site (RIRR; SEQ ID
NO:58); and (f) an .alpha.-MSH sequence SYSMEHFRWGKPV (SEQ ID
NO:1).
[0167] The linker and furin site sequences are introduced by
PCR-based site-directed mutagenesis into the previously constructed
serum albumin-.alpha.-MSH constructs. Two homologous long primers
are designed, with the sequences for the linker and the furin site
at the center, flanked by at least 25 bases homologous to the human
or mouse serum albumin and .alpha.-MSH. During the PCR reaction,
the primers anneal to the circular plasmid (at the homologous
flanking sequences), while the non-homologous (linker and furin)
sequences loop out. The PCR reaction is then digested with DpnI, a
restriction enzyme that recognizes a four base pair consensus
sequence on a methylated template. Therefore, only the PCR product
is left intact, and it is subsequently transformed into competent
bacteria (DH5.alpha. cells). Colonies are picked for DNA
preparation. Because a new restriction site is engineered in the
primer, clones can be chosen after digest with that restriction
enzyme (e.g., BamHI). The DNA is then sequenced for final
confirmation.
[0168] The amino acid sequences of three constructs depicted in
FIG. 4 are as follows: TABLE-US-00007 HLF.alpha.(H9):
MKWVTFISLLFLFSSAYSRGVFRRDAHKSEVAHRFK (SEQ ID NO:59)
DLGEENFKALVLIAFAQYLQQCPFEDHVKLVNEVTE
FAKTCVADESAENCDKSLHTLFGDKLCTVATLRETY
GEMADCCAKQEPERNECFLQHKDDNPNLPRLVRPEV
DVMCTAFHDNEETFLKKYLYEIARRHPYFYAPELLF
FAKRYKAAFTECCQAADKAACLLPKLDELRDEGKAS SAKGGYGGRIRRSYSMEHFRWGKPV;
HLF.alpha.(H4): MKWVTFISLLFLFSSAYSRGVFRRDAHKSEVAHRFK (SEQ ID NO:60)
DLGEENFKALVLIAFAQYLQQCPFEDHVKLVNEVTE
FAKTCVADESAENCDKSLHTLFGDKLCTVATLRETY
GEMADCCAKQEPERNECFLQHKDDNPNLPRLVRPEV
DVMCTAFHDNEETFLKKYLYEIARRHPYFYAPELLF
FAKRYKAAFTECCQAADKAACLLPKLDELRDEGKAS
SAKGGYGGRIRRSYSMEHFRWDEGKASSAKGGYGGR IRRSYSMEHFRWGKPV; and
MLF.alpha.(M2): MKWVTFLLLLFVSGSAFSRGVFRREAHKSEIAHRYN (SEQ ID NO:61)
DLGEQHFKGLVLIAFSQYLQKCSYDEHAKLVQEVTD
FAKTCVADESAANCDKSLHTLFGDKLCAIPNLRENY
GELADCCTKQEPERNECFLQHKDDNPSLPPFERPEA
EAMCTSFKENPTTFMGHYLHEVARRHPYFYAPELLY
YAEQYNEILTQCCAEADKESCLTPKLDGVKEKALVS SVRGGYGGRIRRSYSMEHFRWGKPV.
[0169] Constructs similar to those depicted in FIG. 4 can be
prepared, wherein the .alpha.-MSH containing sequence SYSMEHFRWGKPV
(SEQ ID NO:1) is replaced with another .alpha.-MSH containing
sequence described herein, e.g., ACTH(1-14) (SEQ ID NO:62),
ACTH(1-16) (SEQ ID NO:63), ACTH(1-17) (SEQ ID NO:64), or
SYSMEHFRWGKPVRSKR (SEQ ID NO:69).
[0170] Nucleic acid constructs were also prepared encoding fusion
polypeptides containing a serum albumin signal peptide (mouse or
human), a serum albumin propeptide (mouse or human), the first 195
amino acids of serum albumin (mouse or human), a thrombin cleavage
site (LAPR; SEQ ID NO:81), and an .alpha.-MSH sequence
SYSMEHFRWGKPV (SEQ ID NO:1). The nucleic acid constructs were
subcloned into the expression vector pZYC. The sequences of the
encoded polypeptides were as follows. TABLE-US-00008 H195T:
MKWVTFISLLFLFSSAYSRGVFRRDAHKSEVAHRFK (SEQ ID NO:82;
DLGEENFKALVLIAFAQYLQQCPFEDHVKLVNEVTE human albumin-
FAKTCVADESAENCDKSLHTLFGDKLCTVATLRETY thrombin-.alpha.-
GEMADCCAKQEPERNECFLQHKDDNPNLPRLVRPEV MSH)
DVMCTAFHDNEETFLKKYLYEIARRHPYFYAPELLF
FAKRYKAAFTECCQAADKAACLLPKLDELRDEGKAS SAKLAPRSYSMEHFRWGKPV. Mo195T:
MKWVTFLLLLFVSGSAFSRGVFRREAHKSEIAHRYN (SEQ ID NO:83;
DLGEQHFKGLVLIAFSQYLQKCSYDEHAKLVQEVTD mouse albumin-
FAKTCVADESAANCDKSLHTLFGDKLCAIPNLRENY thrombin-.alpha.-
GELADCCTKQEPERNECFLQHKDDNPSLPPFERPEA MSH).
EAMCTSFKENPTTFMGHYLHEVARRHPYFYAPELLY
YAEQYNEILTQCCAEADKESCLTPKLDGVKEKALVS SVRLAPRSYSMEHFRWGKPV.
Example 3
In Vitro Production of Alpha-MSH
[0171] The mouse melanoma cell line B16/F10 (ATCC, Manassas, Va.)
was grown in Iscove's Modified Dulbecco's Medium with 10% Fetal
Bovine Serum (JRH Biosciences, KS) and was maintained at 37.degree.
C. in humidified 5% CO.sub.2 incubator. Cells were seeded in
six-well plates at 1.times.10.sup.5cells/ml at a volume of 2
ml/well and incubated overnight. Cells were transfected with 3
.mu.g of pCMV-miniPOMC, pIRES-2X miniPOMC, pZYC-miniPOMC, pCMV
empty vector, or pZYC empty vector or were mock transfected using
LipofectAMINE (Life Technologies, MD). The supernatants of the
transfected cells were collected 48 hours post-transfection and
used in a melanin assay.
[0172] Untransfected B16/F10 cells were seeded in 96-well pates at
2.5.times.10.sup.4cells/ml, at 100 .mu.l/well, and were incubated
overnight in a 37.degree. C. incubator. The next day, 100 .mu.l of
supernatant collected from transfected or mock-transfected cells
(see above) was added to appropriate wells. Cells were then
cultured for an additional four days before melanin synthesis was
evaluated.
[0173] Melanin synthesis was measured in two ways, both of which
measure the dark pigmentation that results from the stimulation of
melanin synthesis. In the first method, the pigmentation of cells
was evaluated by visual inspection (both by pelleting transfected
cells and by examining a well of a 96 well plate containing
transfected cells). These experiments demonstrated that cells
transfected with miniPOMC-encoding expression vectors became dark
as compared to cells transfected with an empty vector or mock
transfected cells.
[0174] In the second method, pigmentation was measured by taking
absorbance readings of untransfected cells following the treatments
described above. FIG. 5 shows melanin synthesis induced by the
various miniPOMC-encoding constructs and controls.
Melanogeneis-associated pigmentation was determined by taking
absorbance readings of the wells of a 96 well plate at 405 nm using
a plate reader. The samples depicted in FIG. 5 are as follows: (1)
mock transfected cells; (2) pCMV-Script vector control; (3)
pCMV-miniPOMC; (4) pZYC-miniPOMC; (5) pCMV-miniPOMC; and (6)
pIRES-2X miniPOMC. In determining the absorbance readings presented
for each bar in FIG. 5, 100 .mu.l of supernatant from each of the
six transfectants (or mock transfectants) above was transferred to
a well of a 96 well plate containing 100 .mu.l of media, but no
cells. The absorbance reading taken from this control well was
subtracted from that of its corresponding well containing
untransfected cells (to determine the melanin produced by the
untransfected cells). Commercially obtained alph.alpha.-MSH
peptides (Peninsula Laboratories, CA) were used to generate
standard curves for melanin synthesis at various alpha MSH
concentrations (FIG. 6).
[0175] The constructs depicted in FIGS. 2A-2B were also tested for
their ability to induce pigmentation in B16/F10 cells in the assay
described above. As shown in FIG. 7, the following constructs were
evaluated: (1) pCMV-Script vector control; (2) pCMV-miniPOMC; (3)
pCMV-ACTH(1-14); (4) pCMV-ACTH(1-16); and (5) pCMV-ACTH(1-17).
Absorbance readings were taken as described above. The readings
were normalized to secretory alkaline phosphatase (SEAP)
transfected cells, which corrects for variability in
transfection.
[0176] FIG. 8 depicts the results of a radio-immunoassay (RIA)
which measured standard alpha MSH and supernatants from cells
transfected with various constructs described herein. The samples
depicted in FIG. 8 are as follows: (1) mock transfected cells; (2)
pCMV-Script vector control; (3) pCMV-miniPOMC; (4) pCNP-ACTH(1-14);
(5) pCMV-ACTH(1-16); and (6) pCMV-ACTH(1-17). Because the assay is
competitive, a lower CPM reading indicates higher levels of alpha
MSH in the sample.
[0177] In a RIA, a standard peptide at serial dilutions or samples
that contain target peptides are added together. A primary rabbit
polyclonal antibody to the target peptide is added, followed by
overnight incubation at 4.degree. C. Following incubation, a target
peptide labeled with I.sup.125 is added, followed by another
overnight incubation at 4.degree. C. Following incubation, goat
anti-rabbit IgG serum and normal rabbit serum are added and samples
are incubated at room temperature for 90 minutes. Samples are then
centrifuged at 3,000 rpm for 20 minutes. The pellets are
re-suspended in PBS buffer and transferred to scintillation vials
where CPM is measured by a scintillation counter.
[0178] FIG. 9 depicts the levels of .alpha.-MSH produced in various
cell types trasnfected with constructs described herein. The
expression constructs used were as follows: (1) pCMV-ssMSH; (2)
pZYC-ssMSH; and (3) pIRES-2XssMSH. Production of .alpha.-MSH was
evaluated in B16/F10 mouse melanoma cells, GH3 rat pituitary cells,
RAW mouse macrophage cells, 293 T human kidney cells, and 3T3 mouse
fibroblast cells.
[0179] FIG. 10 depicts amounts of melanin synthesized by
untransfected B16/F10 cells treated with supernatant produced by
B16/F10 cells transfected with .alpha.-MSH/Serum Albumin Fusion
Polypeptides described in Example 2 or negative controls. Negative
control constructs SH195 and SM195 were constructed by placing a
stop codon after the nucleotide sequence encoding the 195 amino
acid human serum albumin protein or mouse serum albumin protein, as
described in Example 2. The results for samples depicted in FIG. 10
are as follows: (1) SH195 (human serum albumin fusion polypeptide);
(2) SM195 (mouse serum albumin fusion polypeptide); (3)
HLF.alpha.(H9); and (4)MLF.alpha.(M2).
Example 4
In Vivo Production of Alpha-MSH
[0180] The ability of the expression vectors described in Example 1
to cause the production of alph.alpha.-MSH in vivo was evaluated as
follows. Six groups of mice, with three animals per group, were set
up and each group was injected with one of the following: (1)
saline; (2) 10 .mu.g alpha MSH Peptide; (3) 100 .mu.g pCMV-Script;
(4) 100 .mu.g pCMV-miniPOMC; (5) 100 .mu.g pZYC-miniPOMC; or (6)
100 .mu.g pIRES-2X miniPOMC. The injections were either intradermal
or intravenous. Mice were bled (intraorbital) at 30 minutes and on
day 1, day 4, day 7, day 11, and day 15 post injection. One hundred
.mu.l of blood was collected and sera was stored at -80.degree. C.
until tested in the in vitro melanin bioassay described in Example
3. To carry out the melanin assay, 10 .mu.l of sera was added to 90
.mu.l of media, and this 100 .mu.l sample was added to a well
containing untransfected B16/F10 cells in 100 .mu.l as described
above. FIGS. 11A and 11B show the in vivo secretion of alpha-MSH
four days following intradermal (FIG. 11A) and intravenous (FIG.
11B) injections.
Example 5
Assays to Detect NF-kB Activation
[0181] One mechanism by which .alpha.-MSH may function is through
the inhibition of NF-kB activation. Specifically, the binding of
.alpha.-MSH to an MCR receptor can prevent the phosphorylation of
the I.kappa.b subunit of the NF-kB-I-kB complex and thereby inhibit
NF-kB activation.
[0182] An assay using a luciferase reporter construct was used to
assess the NF-kB state (active or inactive) when cells transfected
with various .alpha.-MSH expressing plasmids were stimulated to
induce NF-kB activation. Cells were transfected with pNF-kB-Luc, an
.alpha.-MSH vector, and a SEAP expression vector (to correct for
variability in transfection). Cells were then treated with either
TNF-.alpha. or LPS to induce NF-kB activation and thus the
expression of luciferase. Media was collected and an assay was
performed to measure SEAP levels (using a kit provided by TROPIX,
PE Biosystems). Cells were then lysed and luciferase activity was
measured in the cell lysate. To normalize luciferase activity to
the SEAP level, the luciferase count (cps) was divided by the SEAP
count (cps). The fold induction of luciferase activity was then
calculated by dividing the normalized luciferase cps of the treated
sample by the normalized luciferase cps of the untreated
sample.
[0183] FIG. 12 depicts the activation of NF-kB in HeLa cells
treated with TNF-.alpha. and transfected with either an .alpha.-MSH
expressing construct or a control construct. Cells were transfected
with: (1) pZYC empty vector, (2) pZYC-miniPOMC; (3) pSH195 empty
vector; or (4) HLF.alpha.(H9).
[0184] FIG. 13A depicts the activation of NF-kB in RAW 264.7 mouse
macrophage cells treated with 10 .mu.g/ml LPS and transfected with
either an .alpha.-MSH expressing construct or a control construct.
Cells were transfected with: (1) pZYC empty vector, (2)
pZYC-miniPOMC; (3) pSH195 empty vector; or (4) HLF.alpha.(H9). In
addition to RAW 264.7 cells, inhibition of NF-kB activation was
also detected in Sol8 muscle cells treated with 1 or 10 .mu.g/ml
LPS and transfected with a HLF.alpha.(H9)-encoding nucleic acid
construct (not shown).
[0185] FIG. 13B depicts the activation of NF-kB in RAW 264.7 mouse
rhacrophage cells treated with 10 .mu.g/ml LPS and transfected with
either an .alpha.-MSH expressing construct or a control construct.
Cells were transfected with: (1) pCMV empty vector, (2)
pCMV-ACTH(1-14); (3) pCMV-ACTH(1-16); or (4) pCMV-ACTH(1-17).
[0186] FIG. 14 depicts the activation of NF-kB in Sol8 mouse muscle
cells treated with TNF-.alpha. and transfected with either an
.alpha.-MSH expressing construct or a control construct. Cells were
transfected with: (1) peSH195; (2) eHLF.alpha.(H9); or (3)
eMLF.alpha.(M2). The expression vectors peSH195, eHLF.alpha.(H9),
and eMLF.alpha.(M2) encode the polypeptides depicted in FIG. 4
(Example 2) and contain the human elongation factor 1-.alpha.
promoter in place of the CMV promoter.
[0187] In a second assay, direct binding ELISA was used to detect
NF-kB activation. Cells were transfected with an .alpha.-MSH vector
and treated with TNF-.alpha. or LPS to induce NF-kB activation.
After cell lysis, the lysate was added to 96-well plates coated
with an NF-kB-binding oligonucleotide. An anti-NF-kB antibody was
then added to the wells. Following incubation with an anti-IgG
horse radish peroxidase conjugate, color was developed and the
optical density was determined at 450 nm. The Trans-AM.TM. NF-kB
binding assay from Active Motif (Carlsbad, Calif.) was used to
detect NF-kB activation by this method.
[0188] FIG. 15A depicts the activation of NF-kB, as measured by the
Trans-AM.TM. NF-kB binding assay, in RAW and HeLa cells that have
been transfected with either: (1) pZYC empty vector; or (2)
pZYC-miniPOMC. FIG. 15B depicts the activation of NF-kB, as
measured by the Trans-AM.TM. NF-kB binding assay, in RAW cells that
have been transfected with: (1) pCMV empty vector, (2)
pCMV-ACTH(1-14); (3) pCMV-ACTH(1-16); or (4) pCMV-ACTH(1-17).
Example 6
Use of an Alpha-MSH Analog and an Alpha-MSH Encoding Nucleic Acid
to Reduce Severity of Experimental Autoimmune Encephalitis
(EAE)
[0189] The ability of an .alpha.-MSH analog to reduce the severity
of EAE was evaluated as follows. Groups of 10 mice each were
induced with disease by the following protocol. On day 0, each
mouse was administered subcutaneously at the base of the tail 300
.mu.g of Myelin Basic Protein (Sigma) emulsified in Freunds
adjuvant (Sigma) containing 2 mg/ml H37RA (Gibco). The mice also
received three intra-peritoneal injections containing 400 ng of
pertussis toxin (List Biologicals) on days 0, 2, and 7. The animals
were monitored for disease daily starting on day 7. Symptoms were
monitored visually and each mouse was given a daily score according
to the following scale: TABLE-US-00009 Score Symptoms 0 normal
mouse; no overt signs of disease 1 limp tail or hind limp weakness
but not both 2 limp tail and hind leg weakness 3 partial hind leg
paralysis 4 complete hind limp paralysis 5 moribund state
[0190] Beginning on the day that symptoms first appeared, 10
.mu.g/day of .alpha.-MSH analog was administered subcutaneously
each day for a minimum of 14 days. The .alpha.-MSH (4-13) analog
used had the structure
Ac-Cys-Glu-His-DPhe-Arg-Trp-Cys-Lys-Pro-Val-NH.sub.2, with a
disulfide bridge between Cys1 and Cys7. This .alpha.-MSH analog was
obtained from Peninsula Laboratories, Inc. (San Carlos, Calif.).
This analog was described in Cody et al. (1985) J. Med. Chem.
28:583-588. FIG. 16 shows the results of three separate experiments
(10 mice were evaluated in each experiment). The score for each
mouse was totaled at the end of the study and the average
accumulated score for each group of mice is shown in FIG. 16A.
[0191] In a separate set of experiments, EAE was induced as
described above and mice were treated with an .alpha.-MSH encoding
nucleic acid. 100 .mu.g of an .alpha.-MSH encoding plasmid, an
empty vector, or a saline control were injected intramuscularly on
days 0, 7, 14, 21, and 28. FIG. 16B depicts the mean accumulated
clinical score for each group of mice treated with either saline,
pCMVscript, or pCMV-ACTH(1-17). FIG. 16C depicts the mean day of
the onset of clinical symptoms in mice treated with: (1) saline;
(2) pCMV empty vector, (3) pCMV-ACTH(1-14); (4) pCMV-ACTH(1-16); or
(5) pCMV-ACTH(1-17).
Example 7
Use of an Alpha-MSH Analog and an Alpha-MSH Encoding Nucleic Acid
in a Murine Model of Inflammatory Bowel Disease
[0192] Inflammatory Bowel Disease (IBD) was induced in mice by the
administration of trinitrobenzenesulphonic acid (TNBS), in 40%
EtOH, to the mice. The loose stool associated with the IBD induced
in this model resulted in a detectable weight loss in the
TNBS-treated mice. The IBD model is described in, for example,
Keates et al. (2000) Gastroenterology 119:972-82.
[0193] As shown in FIG. 17A, an .alpha.-MSH(4-13) analog (described
in Example 6) decreased the weight loss induced in the IBD model.
The administration of EtOH alone (no TNBS) caused no weight loss in
the animals. The "untreated" mice were given only the TNBS
administration. The aMSH(4-13) mice were given an administration of
TNBS, together with an intranasal administration of the
.alpha.MSH(4-13) analog, which reduced the severity of the
TNBS-induced weight loss. The .alpha.MSH(4-13) analog also
increased the survival of the TNBS-treated animals.
[0194] As shown in FIG. 17B, administration of the pIRES-miniPOMC
vector also reduced the severity of weight loss induced in the IBD
model. The vector was administered by intramuscular injections at
the timepoints indicated in the figure. Administration of the
pIRES-miniPOMC vector also improved the survival of the
TNBS-treated animals.
Example 8
Use of an Alpha-MSH Analog and an Alpha-MSH Encoding Nucleic Acid
in a Murine Model of Obesity
[0195] Leptin -/- mice were used as a model of mammalian obesity to
evaluate the effectiveness of an .alpha.-MSH analog and an
.alpha.-MSH encoding nucleic acid to treat the condition. As shown
in FIG. 18A, leptin -/- mice treated with an .alpha.-MSH(4-13)
analog (as described in Example 6) showed a decrease in weight
gain, as compared to untreated mice. Leptin -/- obese mice were
administered (either intranasally, intrarectally, or
subcutaneously) with 1 .mu.g of the .alpha.-MSH(4-13) analog daily
for three weeks. As shown in FIG. 18B, a reduction in weight gain
was also seen in leptin -/- mice that were provided intranasal
administrations of 100 .mu.g of the pCMV-miniPOMC expression vector
at six day intervals.
Other Embodiments
[0196] It is to be understood that, while the invention has been
described in conjunction with the detailed description thereof, the
foregoing description is intended to illustrate and not limit the
scope of the invention. Other aspects, advantages, and
modifications of the invention are within the scope of the claims
set forth below.
Sequence CWU 0
0
SEQUENCE LISTING <160> NUMBER OF SEQ ID NOS: 83 <210>
SEQ ID NO 1 <211> LENGTH: 13 <212> TYPE: PRT
<213> ORGANISM: Homo sapiens <400> SEQUENCE: 1 Ser Tyr
Ser Met Glu His Phe Arg Trp Gly Lys Pro Val 1 5 10 <210> SEQ
ID NO 2 <211> LENGTH: 3 <212> TYPE: PRT <213>
ORGANISM: Homo sapiens <400> SEQUENCE: 2 Lys Pro Val 1
<210> SEQ ID NO 3 <211> LENGTH: 26 <212> TYPE:
PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 3 Met
Pro Arg Ser Cys Cys Ser Arg Ser Gly Ala Leu Leu Leu Ala Leu 1 5 10
15 Leu Leu Gln Ala Ser Met Glu Val Arg Gly 20 25 <210> SEQ ID
NO 4 <211> LENGTH: 25 <212> TYPE: PRT <213>
ORGANISM: Homo sapiens <400> SEQUENCE: 4 Met Ala Ile Ser Gly
Val Pro Val Leu Gly Phe Phe Ile Ile Ala Val 1 5 10 15 Leu Met Ser
Ala Gln Glu Ser Trp Ala 20 25 <210> SEQ ID NO 5 <211>
LENGTH: 26 <212> TYPE: PRT <213> ORGANISM: Homo sapiens
<400> SEQUENCE: 5 Trp Cys Leu Glu Ser Ser Gln Cys Gln Asp Leu
Thr Thr Glu Ser Asn 1 5 10 15 Leu Leu Glu Cys Ile Arg Ala Cys Lys
Pro 20 25 <210> SEQ ID NO 6 <211> LENGTH: 5 <212>
TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE:
6 Lys Phe Glu Arg Gln 1 5 <210> SEQ ID NO 7 <211>
LENGTH: 5 <212> TYPE: PRT <213> ORGANISM: Homo sapiens
<400> SEQUENCE: 7 Gln Arg Glu Phe Lys 1 5 <210> SEQ ID
NO 8 <211> LENGTH: 23 <212> TYPE: PRT <213>
ORGANISM: Homo sapiens <400> SEQUENCE: 8 Gly Arg Thr Gln Asp
Glu Asn Pro Val Val His Phe Phe Lys Asn Ile 1 5 10 15 Val Thr Pro
Arg Thr Pro Pro 20 <210> SEQ ID NO 9 <211> LENGTH: 22
<212> TYPE: PRT <213> ORGANISM: Homo sapiens
<400> SEQUENCE: 9 Ala Val Tyr Val Tyr Ile Tyr Phe Asn Thr Trp
Thr Thr Cys Gln Phe 1 5 10 15 Ile Ala Phe Pro Phe Lys 20
<210> SEQ ID NO 10 <211> LENGTH: 17 <212> TYPE:
PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 10 Thr
Thr Asn Val Arg Leu Lys Gln Gln Trp Val Asp Tyr Asn Leu Lys 1 5 10
15 Trp <210> SEQ ID NO 11 <211> LENGTH: 20 <212>
TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE:
11 Gln Ile Val Thr Thr Asn Val Arg Leu Lys Gln Gln Trp Val Asp Tyr
1 5 10 15 Asn Leu Lys Trp 20 <210> SEQ ID NO 12 <211>
LENGTH: 7 <212> TYPE: PRT <213> ORGANISM: Homo sapiens
<400> SEQUENCE: 12 Gln Trp Val Asp Tyr Asn Leu 1 5
<210> SEQ ID NO 13 <211> LENGTH: 18 <212> TYPE:
PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 13 Gly
Gly Val Lys Lys Ile His Ile Pro Ser Glu Lys Ile Trp Arg Pro 1 5 10
15 Asp Leu <210> SEQ ID NO 14 <211> LENGTH: 12
<212> TYPE: PRT <213> ORGANISM: Homo sapiens
<400> SEQUENCE: 14 Ala Ile Val Lys Phe Thr Lys Val Leu Leu
Gln Tyr 1 5 10 <210> SEQ ID NO 15 <211> LENGTH: 20
<212> TYPE: PRT <213> ORGANISM: Homo sapiens
<400> SEQUENCE: 15 Trp Thr Pro Pro Ala Ile Phe Lys Ser Tyr
Cys Glu Ile Ile Val Thr 1 5 10 15 His Phe Pro Phe 20 <210>
SEQ ID NO 16 <211> LENGTH: 13 <212> TYPE: PRT
<213> ORGANISM: Homo sapiens <400> SEQUENCE: 16 Met Lys
Leu Gly Thr Trp Thr Tyr Asp Gly Ser Val Val 1 5 10 <210> SEQ
ID NO 17 <211> LENGTH: 13 <212> TYPE: PRT <213>
ORGANISM: Homo sapiens <400> SEQUENCE: 17 Met Lys Leu Gly Ile
Trp Thr Tyr Asp Gly Ser Val Val 1 5 10 <210> SEQ ID NO 18
<211> LENGTH: 9 <212> TYPE: PRT <213> ORGANISM:
Homo sapiens <400> SEQUENCE: 18 Trp Thr Tyr Asp Gly Ser Val
Val Ala 1 5 <210> SEQ ID NO 19 <211> LENGTH: 17
<212> TYPE: PRT <213> ORGANISM: Homo sapiens
<400> SEQUENCE: 19 Ser Cys Cys Pro Asp Thr Pro Tyr Leu Asp
Ile Thr Tyr His Phe Val 1 5 10 15 Met <210> SEQ ID NO 20
<211> LENGTH: 18 <212> TYPE: PRT <213> ORGANISM:
Homo sapiens <400> SEQUENCE: 20
Asp Thr Pro Tyr Leu Asp Ile Thr Tyr His Phe Val Met Gln Arg Leu 1 5
10 15 Pro Leu <210> SEQ ID NO 21 <211> LENGTH: 21
<212> TYPE: PRT <213> ORGANISM: Homo sapiens
<400> SEQUENCE: 21 Phe Ile Val Asn Val Ile Ile Pro Cys Leu
Leu Phe Ser Phe Leu Thr 1 5 10 15 Gly Leu Val Phe Tyr 20
<210> SEQ ID NO 22 <211> LENGTH: 13 <212> TYPE:
PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 22 Leu
Leu Val Ile Val Glu Leu Ile Pro Ser Thr Ser Ser 1 5 10 <210>
SEQ ID NO 23 <211> LENGTH: 19 <212> TYPE: PRT
<213> ORGANISM: Homo sapiens <400> SEQUENCE: 23 Ser Thr
His Val Met Pro Asn Trp Val Arg Lys Val Phe Ile Asp Thr 1 5 10 15
Ile Pro Asn <210> SEQ ID NO 24 <211> LENGTH: 18
<212> TYPE: PRT <213> ORGANISM: Homo sapiens
<400> SEQUENCE: 24 Asn Trp Val Arg Lys Val Phe Ile Asp Thr
Ile Pro Asn Ile Met Phe 1 5 10 15 Phe Ser <210> SEQ ID NO 25
<211> LENGTH: 18 <212> TYPE: PRT <213> ORGANISM:
Homo sapiens <400> SEQUENCE: 25 Ile Pro Asn Ile Met Phe Phe
Ser Thr Met Lys Arg Pro Ser Arg Glu 1 5 10 15 Lys Gln <210>
SEQ ID NO 26 <211> LENGTH: 16 <212> TYPE: PRT
<213> ORGANISM: Homo sapiens <400> SEQUENCE: 26 Ala Ala
Ala Glu Trp Lys Tyr Val Ala Met Val Met Asp His Ile Leu 1 5 10 15
<210> SEQ ID NO 27 <211> LENGTH: 19 <212> TYPE:
PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 27 Ile
Ile Gly Thr Leu Ala Val Phe Ala Gly Arg Leu Ile Glu Leu Asn 1 5 10
15 Gln Gln Gly <210> SEQ ID NO 28 <211> LENGTH: 20
<212> TYPE: PRT <213> ORGANISM: Homo sapiens
<400> SEQUENCE: 28 Gly Gln Thr Ile Glu Trp Ile Phe Ile Asp
Pro Glu Ala Phe Thr Glu 1 5 10 15 Asn Gly Glu Trp 20 <210>
SEQ ID NO 29 <211> LENGTH: 20 <212> TYPE: PRT
<213> ORGANISM: Homo sapiens <400> SEQUENCE: 29 Met Ala
His Tyr Asn Arg Val Pro Ala Leu Pro Phe Pro Gly Asp Pro 1 5 10 15
Arg Pro Tyr Leu 20 <210> SEQ ID NO 30 <211> LENGTH: 15
<212> TYPE: PRT <213> ORGANISM: Homo sapiens
<400> SEQUENCE: 30 Leu Asn Ser Lys Ile Ala Phe Lys Ile Val
Ser Gln Glu Pro Ala 1 5 10 15 <210> SEQ ID NO 31 <211>
LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Homo sapiens
<400> SEQUENCE: 31 Thr Pro Met Phe Leu Leu Ser Arg Asn Thr
Gly Glu Val Arg Thr 1 5 10 15 <210> SEQ ID NO 32 <211>
LENGTH: 21 <212> TYPE: PRT <213> ORGANISM: Homo sapiens
<400> SEQUENCE: 32 Ser Gln Arg His Gly Ser Lys Tyr Leu Ala
Thr Ala Ser Thr Met Asp 1 5 10 15 His Ala Arg His Gly 20
<210> SEQ ID NO 33 <211> LENGTH: 20 <212> TYPE:
PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 33 Arg
Asp Thr Gly Ile Leu Asp Ser Ile Gly Arg Phe Phe Gly Gly Asp 1 5 10
15 Arg Gly Ala Pro 20 <210> SEQ ID NO 34 <211> LENGTH:
20 <212> TYPE: PRT <213> ORGANISM: Homo sapiens
<400> SEQUENCE: 34 Gln Lys Ser His Gly Arg Thr Gln Asp Glu
Asn Pro Val Val His Phe 1 5 10 15 Phe Lys Asn Ile 20 <210>
SEQ ID NO 35 <211> LENGTH: 14 <212> TYPE: PRT
<213> ORGANISM: Homo sapiens <400> SEQUENCE: 35 Asp Glu
Asn Pro Val Val His Phe Phe Lys Asn Ile Val Thr 1 5 10 <210>
SEQ ID NO 36 <211> LENGTH: 15 <212> TYPE: PRT
<213> ORGANISM: Homo sapiens <400> SEQUENCE: 36 Glu Asn
Pro Val Val His Phe Phe Lys Asn Ile Val Thr Pro Arg 1 5 10 15
<210> SEQ ID NO 37 <211> LENGTH: 13 <212> TYPE:
PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 37 His
Phe Phe Lys Asn Ile Val Thr Pro Arg Thr Pro Pro 1 5 10 <210>
SEQ ID NO 38 <211> LENGTH: 14 <212> TYPE: PRT
<213> ORGANISM: Homo sapiens <400> SEQUENCE: 38 Lys Gly
Phe Lys Gly Val Asp Ala Gln Gly Thr Leu Ser Lys 1 5 10 <210>
SEQ ID NO 39 <211> LENGTH: 20 <212> TYPE: PRT
<213> ORGANISM: Homo sapiens <400> SEQUENCE: 39 Val Asp
Ala Gln Gly Thr Leu Ser Lys Ile Phe Lys Leu Gly Gly Arg 1 5 10 15
Asp Ser Arg Ser 20 <210> SEQ ID NO 40 <211> LENGTH: 52
<212> TYPE: PRT <213> ORGANISM: Homo sapiens
<400> SEQUENCE: 40
Met Pro Arg Ser Cys Cys Ser Arg Ser Gly Ala Leu Leu Leu Ala Leu 1 5
10 15 Leu Leu Gln Ala Ser Met Glu Val Arg Gly Trp Cys Leu Glu Ser
Ser 20 25 30 Gln Cys Gln Asp Leu Thr Thr Glu Ser Asn Leu Leu Glu
Cys Ile Arg 35 40 45 Ala Cys Lys Pro 50 <210> SEQ ID NO 41
<211> LENGTH: 5 <212> TYPE: PRT <213> ORGANISM:
Homo sapiens <400> SEQUENCE: 41 Glu His Phe Arg Trp 1 5
<210> SEQ ID NO 42 <211> LENGTH: 70 <212> TYPE:
PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 42 Met
Pro Arg Ser Cys Cys Ser Arg Ser Gly Ala Leu Leu Leu Ala Leu 1 5 10
15 Leu Leu Gln Ala Ser Met Glu Val Arg Gly Trp Cys Leu Glu Ser Ser
20 25 30 Gln Cys Gln Asp Leu Thr Thr Glu Ser Asn Leu Leu Glu Cys
Ile Arg 35 40 45 Ala Cys Lys Pro Arg Glu Gly Lys Arg Ser Tyr Ser
Met Glu His Phe 50 55 60 Arg Trp Gly Lys Pro Val 65 70 <210>
SEQ ID NO 43 <211> LENGTH: 245 <212> TYPE: DNA
<213> ORGANISM: Homo sapiens <220> FEATURE: <221>
NAME/KEY: CDS <222> LOCATION: (21)...(230) <400>
SEQUENCE: 43 aagcttgcgc tgcctggaag atg ccg aga tcg tgc tgc agc cgc
tcg ggg gcc 53 Met Pro Arg Ser Cys Cys Ser Arg Ser Gly Ala 1 5 10
ctg ttg ctg gcc ttg ctg ctt cag gcc tcc atg gaa gtg cgt ggc tgg 101
Leu Leu Leu Ala Leu Leu Leu Gln Ala Ser Met Glu Val Arg Gly Trp 15
20 25 tgc ctg gag agc agc cag tgt cag gac ctc acc acg gaa agc aac
ctg 149 Cys Leu Glu Ser Ser Gln Cys Gln Asp Leu Thr Thr Glu Ser Asn
Leu 30 35 40 ctg gag tgc atc cgg gcc tgc aag ccc cgc gag ggc aag
cgc tcc tac 197 Leu Glu Cys Ile Arg Ala Cys Lys Pro Arg Glu Gly Lys
Arg Ser Tyr 45 50 55 tcc atg gag cac ttc cgc tgg ggc aag ccg gtg
taaggatccc tcgag 245 Ser Met Glu His Phe Arg Trp Gly Lys Pro Val 60
65 70 <210> SEQ ID NO 44 <211> LENGTH: 5 <212>
TYPE: PRT <213> ORGANISM: Artificial Sequence <220>
FEATURE: <223> OTHER INFORMATION: linker sequence <400>
SEQUENCE: 44 Gly Gly Val Gly Gly 1 5 <210> SEQ ID NO 45
<211> LENGTH: 4 <212> TYPE: PRT <213> ORGANISM:
Homo sapiens <400> SEQUENCE: 45 Gly Lys Lys Arg 1 <210>
SEQ ID NO 46 <211> LENGTH: 250 <212> TYPE: DNA
<213> ORGANISM: Homo sapiens <220> FEATURE: <221>
NAME/KEY: CDS <222> LOCATION: (23)...(235) <400>
SEQUENCE: 46 aagcttgcgc gctgcctgga ag atg ccg aga tcg tgc tgc agc
cgc tcg ggg 52 Met Pro Arg Ser Cys Cys Ser Arg Ser Gly 1 5 10 gcc
ctg ttg ctg gcc ttg ctg ctt cag gcc tcc atg gaa gtg cgt ggc 100 Ala
Leu Leu Leu Ala Leu Leu Leu Gln Ala Ser Met Glu Val Arg Gly 15 20
25 tgg tgc ctg gag agc agc cag tgt cag gac ctc acc acg gaa agc aac
148 Trp Cys Leu Glu Ser Ser Gln Cys Gln Asp Leu Thr Thr Glu Ser Asn
30 35 40 ctg ctg gag tgc atc cgg gcc tgc aag ccc cgc gag ggc aag
cgc tcc 196 Leu Leu Glu Cys Ile Arg Ala Cys Lys Pro Arg Glu Gly Lys
Arg Ser 45 50 55 tac tcc atg gag cac ttc cgc tgg ggc aag ccg gtg
ggc taaggatccc 245 Tyr Ser Met Glu His Phe Arg Trp Gly Lys Pro Val
Gly 60 65 70 tcgag 250 <210> SEQ ID NO 47 <211> LENGTH:
71 <212> TYPE: PRT <213> ORGANISM: Homo sapiens
<400> SEQUENCE: 47 Met Pro Arg Ser Cys Cys Ser Arg Ser Gly
Ala Leu Leu Leu Ala Leu 1 5 10 15 Leu Leu Gln Ala Ser Met Glu Val
Arg Gly Trp Cys Leu Glu Ser Ser 20 25 30 Gln Cys Gln Asp Leu Thr
Thr Glu Ser Asn Leu Leu Glu Cys Ile Arg 35 40 45 Ala Cys Lys Pro
Arg Glu Gly Lys Arg Ser Tyr Ser Met Glu His Phe 50 55 60 Arg Trp
Gly Lys Pro Val Gly 65 70 <210> SEQ ID NO 48 <211>
LENGTH: 256 <212> TYPE: DNA <213> ORGANISM: Homo
sapiens <220> FEATURE: <221> NAME/KEY: CDS <222>
LOCATION: (23)...(241) <400> SEQUENCE: 48 aagcttgcgc
gctgcctgga ag atg ccg aga tcg tgc tgc agc cgc tcg ggg 52 Met Pro
Arg Ser Cys Cys Ser Arg Ser Gly 1 5 10 gcc ctg ttg ctg gcc ttg ctg
ctt cag gcc tcc atg gaa gtg cgt ggc 100 Ala Leu Leu Leu Ala Leu Leu
Leu Gln Ala Ser Met Glu Val Arg Gly 15 20 25 tgg tgc ctg gag agc
agc cag tgt cag gac ctc acc acg gaa agc aac 148 Trp Cys Leu Glu Ser
Ser Gln Cys Gln Asp Leu Thr Thr Glu Ser Asn 30 35 40 ctg ctg gag
tgc atc cgg gcc tgc aag ccc cgc gag ggc aag cgc tcc 196 Leu Leu Glu
Cys Ile Arg Ala Cys Lys Pro Arg Glu Gly Lys Arg Ser 45 50 55 tac
tcc atg gag cac ttc cgc tgg ggc aag ccg gtg ggc aag aag 241 Tyr Ser
Met Glu His Phe Arg Trp Gly Lys Pro Val Gly Lys Lys 60 65 70
taaggatccc tcgag 256 <210> SEQ ID NO 49 <211> LENGTH:
73 <212> TYPE: PRT <213> ORGANISM: Homo sapiens
<400> SEQUENCE: 49 Met Pro Arg Ser Cys Cys Ser Arg Ser Gly
Ala Leu Leu Leu Ala Leu 1 5 10 15 Leu Leu Gln Ala Ser Met Glu Val
Arg Gly Trp Cys Leu Glu Ser Ser 20 25 30 Gln Cys Gln Asp Leu Thr
Thr Glu Ser Asn Leu Leu Glu Cys Ile Arg 35 40 45 Ala Cys Lys Pro
Arg Glu Gly Lys Arg Ser Tyr Ser Met Glu His Phe 50 55 60 Arg Trp
Gly Lys Pro Val Gly Lys Lys 65 70 <210> SEQ ID NO 50
<211> LENGTH: 259 <212> TYPE: DNA <213> ORGANISM:
Homo sapiens <220> FEATURE: <221> NAME/KEY: CDS
<222> LOCATION: (23)...(244) <400> SEQUENCE: 50
aagcttgcgc gctgcctgga ag atg ccg aga tcg tgc tgc agc cgc tcg ggg 52
Met Pro Arg Ser Cys Cys Ser Arg Ser Gly 1 5 10 gcc ctg ttg ctg gcc
ttg ctg ctt cag gcc tcc atg gaa gtg cgt ggc 100 Ala Leu Leu Leu Ala
Leu Leu Leu Gln Ala Ser Met Glu Val Arg Gly 15 20 25 tgg tgc ctg
gag agc agc cag tgt cag gac ctc acc acg gaa agc aac 148 Trp Cys Leu
Glu Ser Ser Gln Cys Gln Asp Leu Thr Thr Glu Ser Asn 30 35 40 ctg
ctg gag tgc atc cgg gcc tgc aag ccc cgc gag ggc aag cgc tcc 196 Leu
Leu Glu Cys Ile Arg Ala Cys Lys Pro Arg Glu Gly Lys Arg Ser 45 50
55 tac tcc atg gag cac ttc cgc tgg ggc aag ccg gtg ggc aag aag cgg
244 Tyr Ser Met Glu His Phe Arg Trp Gly Lys Pro Val Gly Lys Lys Arg
60 65 70 taaggatccc tcgag 259 <210> SEQ ID NO 51 <211>
LENGTH: 74 <212> TYPE: PRT
<213> ORGANISM: Homo sapiens <400> SEQUENCE: 51 Met Pro
Arg Ser Cys Cys Ser Arg Ser Gly Ala Leu Leu Leu Ala Leu 1 5 10 15
Leu Leu Gln Ala Ser Met Glu Val Arg Gly Trp Cys Leu Glu Ser Ser 20
25 30 Gln Cys Gln Asp Leu Thr Thr Glu Ser Asn Leu Leu Glu Cys Ile
Arg 35 40 45 Ala Cys Lys Pro Arg Glu Gly Lys Arg Ser Tyr Ser Met
Glu His Phe 50 55 60 Arg Trp Gly Lys Pro Val Gly Lys Lys Arg 65 70
<210> SEQ ID NO 52 <211> LENGTH: 18 <212> TYPE:
PRT <213> ORGANISM: Mus musculus <400> SEQUENCE: 52 Met
Lys Trp Val Thr Phe Leu Leu Leu Leu Phe Val Ser Gly Ser Ala 1 5 10
15 Phe Ser <210> SEQ ID NO 53 <211> LENGTH: 18
<212> TYPE: PRT <213> ORGANISM: Homo sapiens
<400> SEQUENCE: 53 Met Lys Trp Val Thr Phe Ile Ser Leu Leu
Phe Leu Phe Ser Ser Ala 1 5 10 15 Tyr Ser <210> SEQ ID NO 54
<211> LENGTH: 6 <212> TYPE: PRT <213> ORGANISM:
Homo sapiens <400> SEQUENCE: 54 Arg Gly Val Phe Arg Arg 1 5
<210> SEQ ID NO 55 <211> LENGTH: 195 <212> TYPE:
PRT <213> ORGANISM: Mus musculus <400> SEQUENCE: 55 Glu
Ala His Lys Ser Glu Ile Ala His Arg Tyr Asn Asp Leu Gly Glu 1 5 10
15 Gln His Phe Lys Gly Leu Val Leu Ile Ala Phe Ser Gln Tyr Leu Gln
20 25 30 Lys Cys Ser Tyr Asp Glu His Ala Lys Leu Val Gln Glu Val
Thr Asp 35 40 45 Phe Ala Lys Thr Cys Val Ala Asp Glu Ser Ala Ala
Asn Cys Asp Lys 50 55 60 Ser Leu His Thr Leu Phe Gly Asp Lys Leu
Cys Ala Ile Pro Asn Leu 65 70 75 80 Arg Glu Asn Tyr Gly Glu Leu Ala
Asp Cys Cys Thr Lys Gln Glu Pro 85 90 95 Glu Arg Asn Glu Cys Phe
Leu Gln His Lys Asp Asp Asn Pro Ser Leu 100 105 110 Pro Pro Phe Glu
Arg Pro Glu Ala Glu Ala Met Cys Thr Ser Phe Lys 115 120 125 Glu Asn
Pro Thr Thr Phe Met Gly His Tyr Leu His Glu Val Ala Arg 130 135 140
Arg His Pro Tyr Phe Tyr Ala Pro Glu Leu Leu Tyr Tyr Ala Glu Gln 145
150 155 160 Tyr Asn Glu Ile Leu Thr Gln Cys Cys Ala Glu Ala Asp Lys
Glu Ser 165 170 175 Cys Leu Thr Pro Lys Leu Asp Gly Val Lys Glu Lys
Ala Leu Val Ser 180 185 190 Ser Val Arg 195 <210> SEQ ID NO
56 <211> LENGTH: 195 <212> TYPE: PRT <213>
ORGANISM: Homo sapiens <400> SEQUENCE: 56 Asp Ala His Lys Ser
Glu Val Ala His Arg Phe Lys Asp Leu Gly Glu 1 5 10 15 Glu Asn Phe
Lys Ala Leu Val Leu Ile Ala Phe Ala Gln Tyr Leu Gln 20 25 30 Gln
Cys Pro Phe Glu Asp His Val Lys Leu Val Asn Glu Val Thr Glu 35 40
45 Phe Ala Lys Thr Cys Val Ala Asp Glu Ser Ala Glu Asn Cys Asp Lys
50 55 60 Ser Leu His Thr Leu Phe Gly Asp Lys Leu Cys Thr Val Ala
Thr Leu 65 70 75 80 Arg Glu Thr Tyr Gly Glu Met Ala Asp Cys Cys Ala
Lys Gln Glu Pro 85 90 95 Glu Arg Asn Glu Cys Phe Leu Gln His Lys
Asp Asp Asn Pro Asn Leu 100 105 110 Pro Arg Leu Val Arg Pro Glu Val
Asp Val Met Cys Thr Ala Phe His 115 120 125 Asp Asn Glu Glu Thr Phe
Leu Lys Lys Tyr Leu Tyr Glu Ile Ala Arg 130 135 140 Arg His Pro Tyr
Phe Tyr Ala Pro Glu Leu Leu Phe Phe Ala Lys Arg 145 150 155 160 Tyr
Lys Ala Ala Phe Thr Glu Cys Cys Gln Ala Ala Asp Lys Ala Ala 165 170
175 Cys Leu Leu Pro Lys Leu Asp Glu Leu Arg Asp Glu Gly Lys Ala Ser
180 185 190 Ser Ala Lys 195 <210> SEQ ID NO 57 <211>
LENGTH: 5 <212> TYPE: PRT <213> ORGANISM: Artificial
Sequence <220> FEATURE: <223> OTHER INFORMATION: linker
sequence <400> SEQUENCE: 57 Gly Gly Tyr Gly Gly 1 5
<210> SEQ ID NO 58 <211> LENGTH: 4 <212> TYPE:
PRT <213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: furin site <400> SEQUENCE: 58
Arg Ile Arg Arg 1 <210> SEQ ID NO 59 <211> LENGTH: 241
<212> TYPE: PRT <213> ORGANISM: Homo sapiens
<400> SEQUENCE: 59 Met Lys Trp Val Thr Phe Ile Ser Leu Leu
Phe Leu Phe Ser Ser Ala 1 5 10 15 Tyr Ser Arg Gly Val Phe Arg Arg
Asp Ala His Lys Ser Glu Val Ala 20 25 30 His Arg Phe Lys Asp Leu
Gly Glu Glu Asn Phe Lys Ala Leu Val Leu 35 40 45 Ile Ala Phe Ala
Gln Tyr Leu Gln Gln Cys Pro Phe Glu Asp His Val 50 55 60 Lys Leu
Val Asn Glu Val Thr Glu Phe Ala Lys Thr Cys Val Ala Asp 65 70 75 80
Glu Ser Ala Glu Asn Cys Asp Lys Ser Leu His Thr Leu Phe Gly Asp 85
90 95 Lys Leu Cys Thr Val Ala Thr Leu Arg Glu Thr Tyr Gly Glu Met
Ala 100 105 110 Asp Cys Cys Ala Lys Gln Glu Pro Glu Arg Asn Glu Cys
Phe Leu Gln 115 120 125 His Lys Asp Asp Asn Pro Asn Leu Pro Arg Leu
Val Arg Pro Glu Val 130 135 140 Asp Val Met Cys Thr Ala Phe His Asp
Asn Glu Glu Thr Phe Leu Lys 145 150 155 160 Lys Tyr Leu Tyr Glu Ile
Ala Arg Arg His Pro Tyr Phe Tyr Ala Pro 165 170 175 Glu Leu Leu Phe
Phe Ala Lys Arg Tyr Lys Ala Ala Phe Thr Glu Cys 180 185 190 Cys Gln
Ala Ala Asp Lys Ala Ala Cys Leu Leu Pro Lys Leu Asp Glu 195 200 205
Leu Arg Asp Glu Gly Lys Ala Ser Ser Ala Lys Gly Gly Tyr Gly Gly 210
215 220 Arg Ile Arg Arg Ser Tyr Ser Met Glu His Phe Arg Trp Gly Lys
Pro 225 230 235 240 Val <210> SEQ ID NO 60 <211>
LENGTH: 268 <212> TYPE: PRT <213> ORGANISM: Homo
sapiens <400> SEQUENCE: 60 Met Lys Trp Val Thr Phe Ile Ser
Leu Leu Phe Leu Phe Ser Ser Ala 1 5 10 15 Tyr Ser Arg Gly Val Phe
Arg Arg Asp Ala His Lys Ser Glu Val Ala 20 25 30 His Arg Phe Lys
Asp Leu Gly Glu Glu Asn Phe Lys Ala Leu Val Leu 35 40 45 Ile Ala
Phe Ala Gln Tyr Leu Gln Gln Cys Pro Phe Glu Asp His Val 50 55
60
Lys Leu Val Asn Glu Val Thr Glu Phe Ala Lys Thr Cys Val Ala Asp 65
70 75 80 Glu Ser Ala Glu Asn Cys Asp Lys Ser Leu His Thr Leu Phe
Gly Asp 85 90 95 Lys Leu Cys Thr Val Ala Thr Leu Arg Glu Thr Tyr
Gly Glu Met Ala 100 105 110 Asp Cys Cys Ala Lys Gln Glu Pro Glu Arg
Asn Glu Cys Phe Leu Gln 115 120 125 His Lys Asp Asp Asn Pro Asn Leu
Pro Arg Leu Val Arg Pro Glu Val 130 135 140 Asp Val Met Cys Thr Ala
Phe His Asp Asn Glu Glu Thr Phe Leu Lys 145 150 155 160 Lys Tyr Leu
Tyr Glu Ile Ala Arg Arg His Pro Tyr Phe Tyr Ala Pro 165 170 175 Glu
Leu Leu Phe Phe Ala Lys Arg Tyr Lys Ala Ala Phe Thr Glu Cys 180 185
190 Cys Gln Ala Ala Asp Lys Ala Ala Cys Leu Leu Pro Lys Leu Asp Glu
195 200 205 Leu Arg Asp Glu Gly Lys Ala Ser Ser Ala Lys Gly Gly Tyr
Gly Gly 210 215 220 Arg Ile Arg Arg Ser Tyr Ser Met Glu His Phe Arg
Trp Asp Glu Gly 225 230 235 240 Lys Ala Ser Ser Ala Lys Gly Gly Tyr
Gly Gly Arg Ile Arg Arg Ser 245 250 255 Tyr Ser Met Glu His Phe Arg
Trp Gly Lys Pro Val 260 265 <210> SEQ ID NO 61 <211>
LENGTH: 241 <212> TYPE: PRT <213> ORGANISM: Mus
musculus <400> SEQUENCE: 61 Met Lys Trp Val Thr Phe Leu Leu
Leu Leu Phe Val Ser Gly Ser Ala 1 5 10 15 Phe Ser Arg Gly Val Phe
Arg Arg Glu Ala His Lys Ser Glu Ile Ala 20 25 30 His Arg Tyr Asn
Asp Leu Gly Glu Gln His Phe Lys Gly Leu Val Leu 35 40 45 Ile Ala
Phe Ser Gln Tyr Leu Gln Lys Cys Ser Tyr Asp Glu His Ala 50 55 60
Lys Leu Val Gln Glu Val Thr Asp Phe Ala Lys Thr Cys Val Ala Asp 65
70 75 80 Glu Ser Ala Ala Asn Cys Asp Lys Ser Leu His Thr Leu Phe
Gly Asp 85 90 95 Lys Leu Cys Ala Ile Pro Asn Leu Arg Glu Asn Tyr
Gly Glu Leu Ala 100 105 110 Asp Cys Cys Thr Lys Gln Glu Pro Glu Arg
Asn Glu Cys Phe Leu Gln 115 120 125 His Lys Asp Asp Asn Pro Ser Leu
Pro Pro Phe Glu Arg Pro Glu Ala 130 135 140 Glu Ala Met Cys Thr Ser
Phe Lys Glu Asn Pro Thr Thr Phe Met Gly 145 150 155 160 His Tyr Leu
His Glu Val Ala Arg Arg His Pro Tyr Phe Tyr Ala Pro 165 170 175 Glu
Leu Leu Tyr Tyr Ala Glu Gln Tyr Asn Glu Ile Leu Thr Gln Cys 180 185
190 Cys Ala Glu Ala Asp Lys Glu Ser Cys Leu Thr Pro Lys Leu Asp Gly
195 200 205 Val Lys Glu Lys Ala Leu Val Ser Ser Val Arg Gly Gly Tyr
Gly Gly 210 215 220 Arg Ile Arg Arg Ser Tyr Ser Met Glu His Phe Arg
Trp Gly Lys Pro 225 230 235 240 Val <210> SEQ ID NO 62
<211> LENGTH: 14 <212> TYPE: PRT <213> ORGANISM:
Homo sapiens <400> SEQUENCE: 62 Ser Tyr Ser Met Glu His Phe
Arg Trp Gly Lys Pro Val Gly 1 5 10 <210> SEQ ID NO 63
<211> LENGTH: 16 <212> TYPE: PRT <213> ORGANISM:
Homo sapiens <400> SEQUENCE: 63 Ser Tyr Ser Met Glu His Phe
Arg Trp Gly Lys Pro Val Gly Lys Lys 1 5 10 15 <210> SEQ ID NO
64 <211> LENGTH: 17 <212> TYPE: PRT <213>
ORGANISM: Homo sapiens <400> SEQUENCE: 64 Ser Tyr Ser Met Glu
His Phe Arg Trp Gly Lys Pro Val Gly Lys Lys 1 5 10 15 Arg
<210> SEQ ID NO 65 <211> LENGTH: 10 <212> TYPE:
PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 65 Ser
Gly Gly Gly Gly Ser Gly Gly Gly Gly 1 5 10 <210> SEQ ID NO 66
<211> LENGTH: 11 <212> TYPE: PRT <213> ORGANISM:
Homo sapiens <400> SEQUENCE: 66 Gly Gly Gly Gly Ser Gly Gly
Gly Gly Gly Ser 1 5 10 <210> SEQ ID NO 67 <211> LENGTH:
20 <212> TYPE: PRT <213> ORGANISM: Homo sapiens
<400> SEQUENCE: 67 Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly
Ser Gly Gly Gly Gly Ser 1 5 10 15 Gly Gly Gly Gly 20 <210>
SEQ ID NO 68 <211> LENGTH: 17 <212> TYPE: PRT
<213> ORGANISM: Homo sapiens <400> SEQUENCE: 68 Ser Ser
Ser Ser Gly Ser Ser Ser Ser Gly Ser Ser Ser Ser Gly Ser 1 5 10 15
Pro <210> SEQ ID NO 69 <211> LENGTH: 17 <212>
TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE:
69 Ser Tyr Ser Met Glu His Phe Arg Trp Gly Lys Pro Val Arg Ser Lys
1 5 10 15 Arg <210> SEQ ID NO 70 <211> LENGTH: 242
<212> TYPE: PRT <213> ORGANISM: Homo sapiens
<400> SEQUENCE: 70 Met Lys Trp Val Thr Phe Ile Ser Leu Leu
Phe Leu Phe Ser Ser Ala 1 5 10 15 Tyr Ser Arg Gly Val Phe Arg Arg
Asp Ala His Lys Ser Glu Val Ala 20 25 30 His Arg Phe Lys Asp Leu
Gly Glu Glu Asn Phe Lys Ala Leu Val Leu 35 40 45 Ile Ala Phe Ala
Gln Tyr Leu Gln Gln Cys Pro Phe Glu Asp His Val 50 55 60 Lys Leu
Val Asn Glu Val Thr Glu Phe Ala Lys Thr Cys Val Ala Asp 65 70 75 80
Glu Ser Ala Glu Asn Cys Asp Lys Ser Leu His Thr Leu Phe Gly Asp 85
90 95 Lys Leu Cys Thr Val Ala Thr Leu Arg Glu Thr Tyr Gly Glu Met
Ala 100 105 110 Asp Cys Cys Ala Lys Gln Glu Pro Glu Arg Asn Glu Cys
Phe Leu Gln 115 120 125 His Lys Asp Asp Asn Pro Asn Leu Pro Arg Leu
Val Arg Pro Glu Val 130 135 140 Asp Val Met Cys Thr Ala Phe His Asp
Asn Glu Glu Thr Phe Leu Lys 145 150 155 160 Lys Tyr Leu Tyr Glu Ile
Ala Arg Arg His Pro Tyr Phe Tyr Ala Pro 165 170 175 Glu Leu Leu Phe
Phe Ala Lys Arg Tyr Lys Ala Ala Phe Thr Glu Cys 180 185 190 Cys Gln
Ala Ala Asp Lys Ala Ala Cys Leu Leu Pro Lys Leu Asp Glu 195 200 205
Leu Arg Asp Glu Gly Lys Ala Ser Ser Ala Lys Gly Gly Tyr Gly Gly 210
215 220 Arg Ile Arg Arg Ser Tyr Ser Met Glu His Phe Arg Trp Gly Lys
Pro 225 230 235 240 Val Gly <210> SEQ ID NO 71 <211>
LENGTH: 244 <212> TYPE: PRT <213> ORGANISM: Homo
sapiens
<400> SEQUENCE: 71 Met Lys Trp Val Thr Phe Ile Ser Leu Leu
Phe Leu Phe Ser Ser Ala 1 5 10 15 Tyr Ser Arg Gly Val Phe Arg Arg
Asp Ala His Lys Ser Glu Val Ala 20 25 30 His Arg Phe Lys Asp Leu
Gly Glu Glu Asn Phe Lys Ala Leu Val Leu 35 40 45 Ile Ala Phe Ala
Gln Tyr Leu Gln Gln Cys Pro Phe Glu Asp His Val 50 55 60 Lys Leu
Val Asn Glu Val Thr Glu Phe Ala Lys Thr Cys Val Ala Asp 65 70 75 80
Glu Ser Ala Glu Asn Cys Asp Lys Ser Leu His Thr Leu Phe Gly Asp 85
90 95 Lys Leu Cys Thr Val Ala Thr Leu Arg Glu Thr Tyr Gly Glu Met
Ala 100 105 110 Asp Cys Cys Ala Lys Gln Glu Pro Glu Arg Asn Glu Cys
Phe Leu Gln 115 120 125 His Lys Asp Asp Asn Pro Asn Leu Pro Arg Leu
Val Arg Pro Glu Val 130 135 140 Asp Val Met Cys Thr Ala Phe His Asp
Asn Glu Glu Thr Phe Leu Lys 145 150 155 160 Lys Tyr Leu Tyr Glu Ile
Ala Arg Arg His Pro Tyr Phe Tyr Ala Pro 165 170 175 Glu Leu Leu Phe
Phe Ala Lys Arg Tyr Lys Ala Ala Phe Thr Glu Cys 180 185 190 Cys Gln
Ala Ala Asp Lys Ala Ala Cys Leu Leu Pro Lys Leu Asp Glu 195 200 205
Leu Arg Asp Glu Gly Lys Ala Ser Ser Ala Lys Gly Gly Tyr Gly Gly 210
215 220 Arg Ile Arg Arg Ser Tyr Ser Met Glu His Phe Arg Trp Gly Lys
Pro 225 230 235 240 Val Gly Lys Lys <210> SEQ ID NO 72
<211> LENGTH: 245 <212> TYPE: PRT <213> ORGANISM:
Homo sapiens <400> SEQUENCE: 72 Met Lys Trp Val Thr Phe Ile
Ser Leu Leu Phe Leu Phe Ser Ser Ala 1 5 10 15 Tyr Ser Arg Gly Val
Phe Arg Arg Asp Ala His Lys Ser Glu Val Ala 20 25 30 His Arg Phe
Lys Asp Leu Gly Glu Glu Asn Phe Lys Ala Leu Val Leu 35 40 45 Ile
Ala Phe Ala Gln Tyr Leu Gln Gln Cys Pro Phe Glu Asp His Val 50 55
60 Lys Leu Val Asn Glu Val Thr Glu Phe Ala Lys Thr Cys Val Ala Asp
65 70 75 80 Glu Ser Ala Glu Asn Cys Asp Lys Ser Leu His Thr Leu Phe
Gly Asp 85 90 95 Lys Leu Cys Thr Val Ala Thr Leu Arg Glu Thr Tyr
Gly Glu Met Ala 100 105 110 Asp Cys Cys Ala Lys Gln Glu Pro Glu Arg
Asn Glu Cys Phe Leu Gln 115 120 125 His Lys Asp Asp Asn Pro Asn Leu
Pro Arg Leu Val Arg Pro Glu Val 130 135 140 Asp Val Met Cys Thr Ala
Phe His Asp Asn Glu Glu Thr Phe Leu Lys 145 150 155 160 Lys Tyr Leu
Tyr Glu Ile Ala Arg Arg His Pro Tyr Phe Tyr Ala Pro 165 170 175 Glu
Leu Leu Phe Phe Ala Lys Arg Tyr Lys Ala Ala Phe Thr Glu Cys 180 185
190 Cys Gln Ala Ala Asp Lys Ala Ala Cys Leu Leu Pro Lys Leu Asp Glu
195 200 205 Leu Arg Asp Glu Gly Lys Ala Ser Ser Ala Lys Gly Gly Tyr
Gly Gly 210 215 220 Arg Ile Arg Arg Ser Tyr Ser Met Glu His Phe Arg
Trp Gly Lys Pro 225 230 235 240 Val Gly Lys Lys Arg 245 <210>
SEQ ID NO 73 <211> LENGTH: 245 <212> TYPE: PRT
<213> ORGANISM: Homo sapiens <400> SEQUENCE: 73 Met Lys
Trp Val Thr Phe Ile Ser Leu Leu Phe Leu Phe Ser Ser Ala 1 5 10 15
Tyr Ser Arg Gly Val Phe Arg Arg Asp Ala His Lys Ser Glu Val Ala 20
25 30 His Arg Phe Lys Asp Leu Gly Glu Glu Asn Phe Lys Ala Leu Val
Leu 35 40 45 Ile Ala Phe Ala Gln Tyr Leu Gln Gln Cys Pro Phe Glu
Asp His Val 50 55 60 Lys Leu Val Asn Glu Val Thr Glu Phe Ala Lys
Thr Cys Val Ala Asp 65 70 75 80 Glu Ser Ala Glu Asn Cys Asp Lys Ser
Leu His Thr Leu Phe Gly Asp 85 90 95 Lys Leu Cys Thr Val Ala Thr
Leu Arg Glu Thr Tyr Gly Glu Met Ala 100 105 110 Asp Cys Cys Ala Lys
Gln Glu Pro Glu Arg Asn Glu Cys Phe Leu Gln 115 120 125 His Lys Asp
Asp Asn Pro Asn Leu Pro Arg Leu Val Arg Pro Glu Val 130 135 140 Asp
Val Met Cys Thr Ala Phe His Asp Asn Glu Glu Thr Phe Leu Lys 145 150
155 160 Lys Tyr Leu Tyr Glu Ile Ala Arg Arg His Pro Tyr Phe Tyr Ala
Pro 165 170 175 Glu Leu Leu Phe Phe Ala Lys Arg Tyr Lys Ala Ala Phe
Thr Glu Cys 180 185 190 Cys Gln Ala Ala Asp Lys Ala Ala Cys Leu Leu
Pro Lys Leu Asp Glu 195 200 205 Leu Arg Asp Glu Gly Lys Ala Ser Ser
Ala Lys Gly Gly Tyr Gly Gly 210 215 220 Arg Ile Arg Arg Ser Tyr Ser
Met Glu His Phe Arg Trp Gly Lys Pro 225 230 235 240 Val Arg Ser Lys
Arg 245 <210> SEQ ID NO 74 <211> LENGTH: 242
<212> TYPE: PRT <213> ORGANISM: Homo sapiens
<400> SEQUENCE: 74 Met Lys Trp Val Thr Phe Leu Leu Leu Leu
Phe Val Ser Gly Ser Ala 1 5 10 15 Phe Ser Arg Gly Val Phe Arg Arg
Glu Ala His Lys Ser Glu Ile Ala 20 25 30 His Arg Tyr Asn Asp Leu
Gly Glu Gln His Phe Lys Gly Leu Val Leu 35 40 45 Ile Ala Phe Ser
Gln Tyr Leu Gln Lys Cys Ser Tyr Asp Glu His Ala 50 55 60 Lys Leu
Val Gln Glu Val Thr Asp Phe Ala Lys Thr Cys Val Ala Asp 65 70 75 80
Glu Ser Ala Ala Asn Cys Asp Lys Ser Leu His Thr Leu Phe Gly Asp 85
90 95 Lys Leu Cys Ala Ile Pro Asn Leu Arg Glu Asn Tyr Gly Glu Leu
Ala 100 105 110 Asp Cys Cys Thr Lys Gln Glu Pro Glu Arg Asn Glu Cys
Phe Leu Gln 115 120 125 His Lys Asp Asp Asn Pro Ser Leu Pro Pro Phe
Glu Arg Pro Glu Ala 130 135 140 Glu Ala Met Cys Thr Ser Phe Lys Glu
Asn Pro Thr Thr Phe Met Gly 145 150 155 160 His Tyr Leu His Glu Val
Ala Arg Arg His Pro Tyr Phe Tyr Ala Pro 165 170 175 Glu Leu Leu Tyr
Tyr Ala Glu Gln Tyr Asn Glu Ile Leu Thr Gln Cys 180 185 190 Cys Ala
Glu Ala Asp Lys Glu Ser Cys Leu Thr Pro Lys Leu Asp Gly 195 200 205
Val Lys Glu Lys Ala Leu Val Ser Ser Val Arg Gly Gly Tyr Gly Gly 210
215 220 Arg Ile Arg Arg Ser Tyr Ser Met Glu His Phe Arg Trp Gly Lys
Pro 225 230 235 240 Val Gly <210> SEQ ID NO 75 <211>
LENGTH: 244 <212> TYPE: PRT <213> ORGANISM: Homo
sapiens <400> SEQUENCE: 75 Met Lys Trp Val Thr Phe Leu Leu
Leu Leu Phe Val Ser Gly Ser Ala 1 5 10 15 Phe Ser Arg Gly Val Phe
Arg Arg Glu Ala His Lys Ser Glu Ile Ala 20 25 30 His Arg Tyr Asn
Asp Leu Gly Glu Gln His Phe Lys Gly Leu Val Leu 35 40 45 Ile Ala
Phe Ser Gln Tyr Leu Gln Lys Cys Ser Tyr Asp Glu His Ala 50 55 60
Lys Leu Val Gln Glu Val Thr Asp Phe Ala Lys Thr Cys Val Ala Asp 65
70 75 80 Glu Ser Ala Ala Asn Cys Asp Lys Ser Leu His Thr Leu Phe
Gly Asp 85 90 95 Lys Leu Cys Ala Ile Pro Asn Leu Arg Glu Asn Tyr
Gly Glu Leu Ala 100 105 110 Asp Cys Cys Thr Lys Gln Glu Pro Glu Arg
Asn Glu Cys Phe Leu Gln 115 120 125 His Lys Asp Asp Asn Pro Ser Leu
Pro Pro Phe Glu Arg Pro Glu Ala 130 135 140
Glu Ala Met Cys Thr Ser Phe Lys Glu Asn Pro Thr Thr Phe Met Gly 145
150 155 160 His Tyr Leu His Glu Val Ala Arg Arg His Pro Tyr Phe Tyr
Ala Pro 165 170 175 Glu Leu Leu Tyr Tyr Ala Glu Gln Tyr Asn Glu Ile
Leu Thr Gln Cys 180 185 190 Cys Ala Glu Ala Asp Lys Glu Ser Cys Leu
Thr Pro Lys Leu Asp Gly 195 200 205 Val Lys Glu Lys Ala Leu Val Ser
Ser Val Arg Gly Gly Tyr Gly Gly 210 215 220 Arg Ile Arg Arg Ser Tyr
Ser Met Glu His Phe Arg Trp Gly Lys Pro 225 230 235 240 Val Gly Lys
Lys <210> SEQ ID NO 76 <211> LENGTH: 245 <212>
TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE:
76 Met Lys Trp Val Thr Phe Leu Leu Leu Leu Phe Val Ser Gly Ser Ala
1 5 10 15 Phe Ser Arg Gly Val Phe Arg Arg Glu Ala His Lys Ser Glu
Ile Ala 20 25 30 His Arg Tyr Asn Asp Leu Gly Glu Gln His Phe Lys
Gly Leu Val Leu 35 40 45 Ile Ala Phe Ser Gln Tyr Leu Gln Lys Cys
Ser Tyr Asp Glu His Ala 50 55 60 Lys Leu Val Gln Glu Val Thr Asp
Phe Ala Lys Thr Cys Val Ala Asp 65 70 75 80 Glu Ser Ala Ala Asn Cys
Asp Lys Ser Leu His Thr Leu Phe Gly Asp 85 90 95 Lys Leu Cys Ala
Ile Pro Asn Leu Arg Glu Asn Tyr Gly Glu Leu Ala 100 105 110 Asp Cys
Cys Thr Lys Gln Glu Pro Glu Arg Asn Glu Cys Phe Leu Gln 115 120 125
His Lys Asp Asp Asn Pro Ser Leu Pro Pro Phe Glu Arg Pro Glu Ala 130
135 140 Glu Ala Met Cys Thr Ser Phe Lys Glu Asn Pro Thr Thr Phe Met
Gly 145 150 155 160 His Tyr Leu His Glu Val Ala Arg Arg His Pro Tyr
Phe Tyr Ala Pro 165 170 175 Glu Leu Leu Tyr Tyr Ala Glu Gln Tyr Asn
Glu Ile Leu Thr Gln Cys 180 185 190 Cys Ala Glu Ala Asp Lys Glu Ser
Cys Leu Thr Pro Lys Leu Asp Gly 195 200 205 Val Lys Glu Lys Ala Leu
Val Ser Ser Val Arg Gly Gly Tyr Gly Gly 210 215 220 Arg Ile Arg Arg
Ser Tyr Ser Met Glu His Phe Arg Trp Gly Lys Pro 225 230 235 240 Val
Gly Lys Lys Arg 245 <210> SEQ ID NO 77 <211> LENGTH:
245 <212> TYPE: PRT <213> ORGANISM: Homo sapiens
<400> SEQUENCE: 77 Met Lys Trp Val Thr Phe Leu Leu Leu Leu
Phe Val Ser Gly Ser Ala 1 5 10 15 Phe Ser Arg Gly Val Phe Arg Arg
Glu Ala His Lys Ser Glu Ile Ala 20 25 30 His Arg Tyr Asn Asp Leu
Gly Glu Gln His Phe Lys Gly Leu Val Leu 35 40 45 Ile Ala Phe Ser
Gln Tyr Leu Gln Lys Cys Ser Tyr Asp Glu His Ala 50 55 60 Lys Leu
Val Gln Glu Val Thr Asp Phe Ala Lys Thr Cys Val Ala Asp 65 70 75 80
Glu Ser Ala Ala Asn Cys Asp Lys Ser Leu His Thr Leu Phe Gly Asp 85
90 95 Lys Leu Cys Ala Ile Pro Asn Leu Arg Glu Asn Tyr Gly Glu Leu
Ala 100 105 110 Asp Cys Cys Thr Lys Gln Glu Pro Glu Arg Asn Glu Cys
Phe Leu Gln 115 120 125 His Lys Asp Asp Asn Pro Ser Leu Pro Pro Phe
Glu Arg Pro Glu Ala 130 135 140 Glu Ala Met Cys Thr Ser Phe Lys Glu
Asn Pro Thr Thr Phe Met Gly 145 150 155 160 His Tyr Leu His Glu Val
Ala Arg Arg His Pro Tyr Phe Tyr Ala Pro 165 170 175 Glu Leu Leu Tyr
Tyr Ala Glu Gln Tyr Asn Glu Ile Leu Thr Gln Cys 180 185 190 Cys Ala
Glu Ala Asp Lys Glu Ser Cys Leu Thr Pro Lys Leu Asp Gly 195 200 205
Val Lys Glu Lys Ala Leu Val Ser Ser Val Arg Gly Gly Tyr Gly Gly 210
215 220 Arg Ile Arg Arg Ser Tyr Ser Met Glu His Phe Arg Trp Gly Lys
Pro 225 230 235 240 Val Arg Ser Lys Arg 245 <210> SEQ ID NO
78 <211> LENGTH: 74 <212> TYPE: PRT <213>
ORGANISM: Homo sapiens <400> SEQUENCE: 78 Met Pro Arg Ser Cys
Cys Ser Arg Ser Gly Ala Leu Leu Leu Ala Leu 1 5 10 15 Leu Leu Gln
Ala Ser Met Glu Val Arg Gly Trp Cys Leu Glu Ser Ser 20 25 30 Gln
Cys Gln Asp Leu Thr Thr Glu Ser Asn Leu Leu Glu Cys Ile Arg 35 40
45 Ala Cys Lys Pro Arg Glu Gly Lys Arg Ser Tyr Ser Met Glu His Phe
50 55 60 Arg Trp Gly Lys Pro Val Arg Ser Lys Arg 65 70 <210>
SEQ ID NO 79 <211> LENGTH: 259 <212> TYPE: DNA
<213> ORGANISM: Homo sapiens <220> FEATURE: <221>
NAME/KEY: CDS <222> LOCATION: (23)...(244) <400>
SEQUENCE: 79 aagcttgcgc gctgcctgga ag atg ccg aga tcg tgc tgc agc
cgc tcg ggg 52 Met Pro Arg Ser Cys Cys Ser Arg Ser Gly 1 5 10 gcc
ctg ttg ctg gcc ttg ctg ctt cag gcc tcc atg gaa gtg cgt ggc 100 Ala
Leu Leu Leu Ala Leu Leu Leu Gln Ala Ser Met Glu Val Arg Gly 15 20
25 tgg tgc ctg gag agc agc cag tgt cag gac ctc acc acg gaa agc aac
148 Trp Cys Leu Glu Ser Ser Gln Cys Gln Asp Leu Thr Thr Glu Ser Asn
30 35 40 ctg ctg gag tgc atc cgg gcc tgc aag ccc cgc gag ggc aag
cgc tcc 196 Leu Leu Glu Cys Ile Arg Ala Cys Lys Pro Arg Glu Gly Lys
Arg Ser 45 50 55 tac tcc atg gag cac ttc cgc tgg ggc aag ccg gtg
cgg tcc aag cgc 244 Tyr Ser Met Glu His Phe Arg Trp Gly Lys Pro Val
Arg Ser Lys Arg 60 65 70 taaggatccc tcgag 259 <210> SEQ ID NO
80 <211> LENGTH: 4 <212> TYPE: PRT <213>
ORGANISM: Homo sapiens <400> SEQUENCE: 80 Arg Ser Lys Arg 1
<210> SEQ ID NO 81 <211> LENGTH: 4 <212> TYPE:
PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 81 Leu
Ala Pro Arg 1 <210> SEQ ID NO 82 <211> LENGTH: 236
<212> TYPE: PRT <213> ORGANISM: Homo sapiens
<400> SEQUENCE: 82 Met Lys Trp Val Thr Phe Ile Ser Leu Leu
Phe Leu Phe Ser Ser Ala 1 5 10 15 Tyr Ser Arg Gly Val Phe Arg Arg
Asp Ala His Lys Ser Glu Val Ala 20 25 30 His Arg Phe Lys Asp Leu
Gly Glu Glu Asn Phe Lys Ala Leu Val Leu 35 40 45 Ile Ala Phe Ala
Gln Tyr Leu Gln Gln Cys Pro Phe Glu Asp His Val 50 55 60 Lys Leu
Val Asn Glu Val Thr Glu Phe Ala Lys Thr Cys Val Ala Asp 65 70 75 80
Glu Ser Ala Glu Asn Cys Asp Lys Ser Leu His Thr Leu Phe Gly Asp 85
90 95 Lys Leu Cys Thr Val Ala Thr Leu Arg Glu Thr Tyr Gly Glu Met
Ala 100 105 110 Asp Cys Cys Ala Lys Gln Glu Pro Glu Arg Asn Glu Cys
Phe Leu Gln 115 120 125 His Lys Asp Asp Asn Pro Asn Leu Pro Arg Leu
Val Arg Pro Glu Val 130 135 140 Asp Val Met Cys Thr Ala Phe His Asp
Asn Glu Glu Thr Phe Leu Lys 145 150 155 160 Lys Tyr Leu Tyr Glu Ile
Ala Arg Arg His Pro Tyr Phe Tyr Ala Pro 165 170 175
Glu Leu Leu Phe Phe Ala Lys Arg Tyr Lys Ala Ala Phe Thr Glu Cys 180
185 190 Cys Gln Ala Ala Asp Lys Ala Ala Cys Leu Leu Pro Lys Leu Asp
Glu 195 200 205 Leu Arg Asp Glu Gly Lys Ala Ser Ser Ala Lys Leu Ala
Pro Arg Ser 210 215 220 Tyr Ser Met Glu His Phe Arg Trp Gly Lys Pro
Val 225 230 235 <210> SEQ ID NO 83 <211> LENGTH: 236
<212> TYPE: PRT <213> ORGANISM: Mus musculus
<400> SEQUENCE: 83 Met Lys Trp Val Thr Phe Leu Leu Leu Leu
Phe Val Ser Gly Ser Ala 1 5 10 15 Phe Ser Arg Gly Val Phe Arg Arg
Glu Ala His Lys Ser Glu Ile Ala 20 25 30 His Arg Tyr Asn Asp Leu
Gly Glu Gln His Phe Lys Gly Leu Val Leu 35 40 45 Ile Ala Phe Ser
Gln Tyr Leu Gln Lys Cys Ser Tyr Asp Glu His Ala 50 55 60 Lys Leu
Val Gln Glu Val Thr Asp Phe Ala Lys Thr Cys Val Ala Asp 65 70 75 80
Glu Ser Ala Ala Asn Cys Asp Lys Ser Leu His Thr Leu Phe Gly Asp 85
90 95 Lys Leu Cys Ala Ile Pro Asn Leu Arg Glu Asn Tyr Gly Glu Leu
Ala 100 105 110 Asp Cys Cys Thr Lys Gln Glu Pro Glu Arg Asn Glu Cys
Phe Leu Gln 115 120 125 His Lys Asp Asp Asn Pro Ser Leu Pro Pro Phe
Glu Arg Pro Glu Ala 130 135 140 Glu Ala Met Cys Thr Ser Phe Lys Glu
Asn Pro Thr Thr Phe Met Gly 145 150 155 160 His Tyr Leu His Glu Val
Ala Arg Arg His Pro Tyr Phe Tyr Ala Pro 165 170 175 Glu Leu Leu Tyr
Tyr Ala Glu Gln Tyr Asn Glu Ile Leu Thr Gln Cys 180 185 190 Cys Ala
Glu Ala Asp Lys Glu Ser Cys Leu Thr Pro Lys Leu Asp Gly 195 200 205
Val Lys Glu Lys Ala Leu Val Ser Ser Val Arg Leu Ala Pro Arg Ser 210
215 220 Tyr Ser Met Glu His Phe Arg Trp Gly Lys Pro Val 225 230
235
* * * * *